Topic index

 

A detailed list of topics on follicular lymphoma is covered here:

–> diagnostic  and  treatment  information  including  information  on  new  drugs.

–> natural  strategies  targeted  to  follicular  lymphoma  linking  lifestyle  to  optimal  genetic  expression.

Upon  completion of the registration process and becoming a member you will have access to the material listed here.

 

 

  A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

 

A

Acetyl L-Carnitine,  June 2022 Newsletter, p. 19-21

Acid/Alkaline Myth, Article #3, p.76

AHCC, December 2014 Newsletter, p. 11

Akkermansia,  October 2023 Newsletter, p. 3-11

Alcohol

  • Effects of alcohol consumption on sleep, October 2022 Newsletter, p. 6-8
  • “Beer and Follicular Lymphoma: It May Surprise You!”,  December 2022 Mid Month Newsletter, p. 1-6; December 2019 Newsletter, p. 6-7; December 2018 Newsletter, p. 4-11
  • Research on alcohol consumption and incidence of lymphoma, October 2014 Newsletter, p. 24-26; November 2013 Newsletter, p. 9-11

AMPK

  • Epigenetic upregulation of AMPK through use of the targeted natural strategies, Article #10, 17-19; Article #11, p. 6-7
  • AMPK and protein Myc, Article #11, p.14
  • Enzyme AMPK helps restrict lymphoma cell growth, Article #10, p. 19-19: February 2013 Newsletter, p. 10-12

Amino Acids

  • Obtaining essential amino acids from food,  August 2024 Newsletter, p. 13-17
  • Adequate, balanced intake of all 9 essential amino acids vital for healthy immunity, January 2015 Newsletter, p. 17-18; December 2013 Newsletter, p. 7-12
  • Methionine, meatless burgers, and pea protein, July 2019 Newsletter, p. 15-19
  • Methionine and its critical role in methylation, May 2014 Newsletter, p. 8-10
  • Blood test for amino acids, Article #7, p.41-42; Article #5, p. 28

Anemia, May 2023 Mid Month Newsletter, p.1-8

Angiogenesis

  • Anti-angiogenic epigenetic effects of ellagic acid, Article #10, p.25-26; Article #11, p. 6; May 2016 Newsletter, p. 15-20
  • Angiogenesis and ellagic acid, Article #10, p. 25-26

Antioxidants , August 2014 Newsletter, p. 15; March 2013 Newsletter, p. 13-15;  Article #7, p. 13-17 

Anxiety,  “Managing Anxiety 2020 Style”, August 2020 Newsletter, p. 2-9

Apples, September 2019 Newsletter, p. 18-19; February 2013 Newsletter, p. 13-14; December 2015 Newsletter, p.11-12

Apple Peel Powder,  May 2024 Newsletter, p. 10-12; October 2023 Newsletter, p.10

Autophagy, October 2018 Newsletter, p. 10-13; January 2018 Newsletter, p. 3-7

Aspartame (Nutrasweet)

  • Potentially harmful epigenetic effects of aspartame, Article #10, p. 26-27; Article #11, p.6, January 2015 Newsletter, p. 15-17
  • Study finds association between aspartame intake in diet sodas and incidence of NHL, December 2012 Newsletter, p. 15-16

Aspirin, April 2018 Newsletter, p.6; November 2016 Newsletter, p. 15

 

[ return to top ]

_________________________________________

B

B Symptoms and Transformation, Article #4, p. 5-6; Article #2, p. 34

BCCA (British Columbia Cancer Agency)

  • Drs. Connors, Gascoyne and Marra’s genomic research on lymphoma, August 2014 Newsletter, p. 29

bcl-2 Gene, July 2010 Newsletter, p. 18-19

Beets, July 2016 Newsletter, p. 19-20

Bendamustine (Treanda)

  • Trial results from 2023 comparing Bendamustine to Revilimid for a first treatment, April 2024 Newsletter, p. 8-9
  • Use of bendamustine in elderly patients, September 2021 Newsletter, p. 16-17
  • Bendamustine — research results for discontinuation after 4 cycles, September 2021 Newletter, p. 15-16
  • Genetic test developed based on m7 research that helps to predict treatment effectiveness, February 2020 Newsletter, p.17-19
  • Results of the BRIGHT trial, comparing R-Benda to R-CHOP or R-CVP, May 2019 Newsletter, p. 8-9
  • Effectiveness of  Bendamustine vs. CHOP compared in Phase III trial, July 2017 Newsletter, p. 14-16
  • Analysis of GADOLIN clinical trial results which compared Bendamustine to Gazyva-Bendamustine combo, May 2016 Newsletter, p. 4-6
  • Treatment options in the event of relapse after treatment with R-Benda, October 2015 Newsletter, p. 13-19
  • General information, Article #6, p.12-13
  • Comparative data for R-Bendamustine and R-CHOP as choice for initial treatment, Article # 7, p. 27
  • Follicular lymphoma survivors with a mutated EZH2 gene at diagnosis — implications for taking R-CHOP vs. R-Bendamustine, October 2022 Mid Month Newsletter, p. 2-6

Benzene

  • Benzene, and products containing it (petrochemical products and solvents), is a toxic exposure risk for fNHL survivors, May 2017 Newsletter, p. 9-10

Berries

  • Blueberries and blackberries can help increase gut bacteria akkermansia, October 2023 Newsletter, p. 9
  • Red berries interact with gut bacteria to strengthen gut barrier and activate mitochondria, April 2019 Newsletter, p. 12-1

Bexxar

  • “Bexxar Bye Bye”, September 2013 Newsletter, p. 21-13

Bile Acids,  July 2022 Mid Month Newsletter, p. 9-11; July 2021 Newsletter, p. 3-12

Biomarkers

  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in follicular lymphoma patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Prognostic significance of key biomarkers in pathology reports, Article #5, p. 17-18

Biospecific Antibodies,  April 2024 Newsletter, p. 5-7; July 2022 Newsletter, p. 15-17;  April 2022 Newsletter, p. 16

Bisphenol A (BPA)

  • 2022 update on BPA’s toxic impact on follicular lymphoma, March 2022 Newsletter, p. 10-16
  • BPA overactivates gene EZH2 creating adverse epigenetic impacts for follicular lymphoma survivors, February 2020 Newsletter, p. 15-17; March 2019 Newsletter, p. 19-22; September 2017 Newsletter, p.4-11; April 2018 Newsletter, p. 9-10; May 2017 Newsletter, p. 12-14; January 2016 Newsletter, p. 2-8; September 2016 Newsletter, p.5
  • BPA and consumption of beer in cans,  December 2022 Mid Month Newsletter, p. 2-6

Blood Stem Cells

  • Urolithin A associated with blood stem cell restoration,  January 2024 Newsletter, p. 3-10

Blood Tests

  • Standard blood test results can be used to calculate the Glasgow Prognostic Score (GPS), an inflammation-related prognostic indicator than can be used for follicular lymphoma,  September 2023 Newsletter, p. 2-6
  • Hemoglobin and Lactate Dehydrogenase (LDH) — what they mean for lymphoma survivors, March 2022 Mid Month Newsletter, p. 2-15
  • Absolute lymphocyte count (ALC) and platelets (what they mean for lymphoma survivors), February 2022 Mid Month Newsletter, p. 1-9; October 2022 Newsletter, p. 15-18
  • How to calculate lymphocyte/monocyte (Ly/Mo) ratio from blood test results, September 2022 Mid Month Newsletter, p. 3-7 and October 2022 Newsletter, p. 12-19
  • Essential information on standard blood tests for fNHL patients, Article #5, p. 20-24
  • Lymphocyte and hemoglobin readings in blood tests, Article #5, p. 21-23
  • How diet can affect blood tests results, Article #7, p. 39-41
  • Non-standard blood tests useful for fNHL patients, Article #5. p. 25-28
  • Why WBC results need to be supplemented with tests for immunoglobulin levels, May 2013 Newsletter, p. 11-13
  • FBG (fasting blood glucose) test,  Article #5, p.27; October 2014 Newsletter, p. 13-15; March 2014 Newsletter, p. 19; Article #7, p. 44-45

Bowel Concerns,  April 2017 Newsletter, p. 7-12; October 2016 Newsletter, p. 4-13; Article #7, p. 45-47; August 2018 Newsletter, p. 7; August 2014 Newsletter, p. 24-25; June 2014 Newsletter, p. 17-20; February 2013 Newsletter, p. 16-17

Broccoli ,  June 2019 Newsletter, p. 4-5;  April 2015 Newsletter, p. 16-17

Bulky Tumors, Article #6, p. 7

Butyrate,  September 2022 Newsletter, p. 12-13; October 2020 Newsletter, p. 11-12; September 2019 Newsletter, p. 5-13; November 2019 Newsletter, p. 10-15

[ return to top ]

________________________________________________

C

Cannabinoids

  • Effects of cannabis products on sleep, October 2022 Newsletter, p. 4-6
  • “Cannabinoids and the “bliss gene”, November 2019 Newsletter, p. 2-6
  • General information: August 2018 Newsletter, p. 19-21; January 2017 Newsletter, p. 11-14

CAR-NK

  • “Innovative New Lymphoma Treatment with Impressive Human Trial Results”,  November 2023 Newsletter, p. 2-14

Carrageenan, May 2014 Newsletter, p. 7-8

Carbohydrates

  • “You Asked About Bread”, November 2014 Newsletter, p. 9-10
  • Potentially cancer-promoting epigenetic effects of a high carbohydrate diet, Article #10, p. 22-24; Article #11, p. 10-11, February 2015 Newsletter, p. 20-21
  • Dietary suggestions for fNHL patients regarding daily carbohydrate intake, mid-November 2020 Newsletter, p. 2-5

Cell (genetic) signaling pathways and cancer, Article #10, p. 9-12

Chemotherapy and Optimization Strategies

  • Summary of recommended chemo optimization strategies for lymphoma survivors, April 2022 Newsletter, p. 17-21
  • ” Chemo: Optimal Response for a Clear Pathway Ahead”,  November 2021 Newsletter, p. 2-10
  • Failure to follow chemo optimization strategies in Article #8 is a strategic error in the management of follicular lymphoma, July 2015 Newsletter, p. 21-22
  • Clear out the chemo debris to optimize the eradication phase (resolvins), October 2021 Newsletter, p. 14-18
  • Update on the benefits of using fish oil during chemotherapy, September 2021 Newsletter, p. 9-13
  • Natural strategies can improve chemotherapy effectiveness, April 2018 Newsletter, p. 4-7
  • “Preparing for treatment — Things to Know Beforehand”, February 2020 Newsletter, p. 5-15
  • Special preparations to make before day of treatment, February 2020 Newsletter, p. 11-15
  • The importance of making sure your vitamin D level is optimized before taking treatment, January 2020 Newsletter, p. 17-19
  • Time of day important for female lymphoma patients undergoing chemotherapy, April 2024 Newsletter p. 9-11
  • Exercise during chemotherapy, Article #8, p 6&13, Article #9, p. 8-9; November 2017 Newsletter, p. 12-13; November 2016 Newsletter, p. 4-5; November 2014 Newsletter, p. 14-16
  • Chemotherapies used to combat transformation, Article #4, p.8-12
  • “New Drug Reduces Chemo Side-Effects”, September 2016 Newsletter, p. 22-23
  • Effectiveness of chemotherapy in mice enhanced by healthy gut bacteria, Article #8, p.17-18; December 2013 Newsletter, p. 18-19
  • Probiotics and chemotherapy, Article #11, p. 12
  • Dietary and lifestyle strategies during chemo”, Article #8
  • Dietary and lifestyle strategies recovering from chemo, Article #9
  • Suggested routine on days of chemo treatment, Article #8, p. 7-11
  • Hyperthermia/ Hot Baths during chemotherapy, Article #8, p. 8-11; Article #7, p. 25-26
  • General daily guidelines while in chemo treatment cycle, Article #9, p. 8-9
  • Chemotherapy optimization strategies, Article #8
  • Chemotherapy and Vitamin D, Article #8, p. 5-6 & p.12
  • Brisk walk on day of chemotherapy, Article #8, p. 7-11
  • Fish oil supplementation during chemotherapy, Article #8, p.6-7 & 12-13 Article #11, p. 12
  • Vitamin supplementation during chemotherapy, Article #8, p. 11-15
  • Supplements to avoid during chemotherapy, Article #8, p. 16-17
  • Dangers of glutamine supplements during chemotherapy, Article #8, p. 16-17
  • Preparing beforehand for chemotherapy, Article #8, p. 4-7
  • The importance of sleep during chemotherapy treatments, Article #8, p. 19-20

Cheson, Dr. Bruce

  • Commentary on maintenance rituximab from a prominent lymphoma specialist, January 2014 Newsletter, p. 17-18; September 2012 Newsletter, p. 4-6

Chlorambucil (Leukeran)

  • Chlorambucil update September 2018 (with new links), September 2018 Newsletter, p. 13-15
  • “Doctors Using Chlorambucil to Treat Follicular Lymphoma”, October 2014 Newsletter, p. 22-24
  • “New Research Shows Outstanding Results with Chlorambucil”, August 2014 Newsletter, p. 4-7
  • “Chlorambucil … Still a Good Option”, April 2014 Newsletter, p. 15-18
  • Lymphoma Survival members stories of success, December 2016 Newsletter, p. 16-17
  • General information, Article #6, p.15-16;  Article #7, p. 17-18
  • Research on highly effective outcomes for using chlorambucil in the treatment of mantle cell lymphoma, April 2011 Newsletter, p. 14-15, January 2011 Newsletter, p. 14-15
  • Why so little use?, Article #6, p.36-43
  • Updated protocol for “pulsing mode”, August 2010 Newsletter, p. 20

Choline, November 2019 Newsletter, p. 7-8

Chronic Hidden Infection

  • Association between infection and first location of nodes, February 2014 Newsletter, p. 13-17
  • “Follicular Lymphoma and Infections: Hidden, Active and Inflammation”, October 2018 Newsletter, p. 14-17
  • April 2013 Newsletter, p. 12-17; Article #3, p. 76

Cinnamon

  • Epigenetic anti-cancer effects of cinnamon, Article #11, p.6
  • August 2013 Newsletter, p. 28-29; April 2013 Newsletter, p. 7-8

Clinical Remission

  • “A Perfect Treatment is Only Part Way There”, August 2020 Newsletter, p. 10-12
  • “Finished Treatment? Now What?”, March 2019 Newsletter, p.5-13
  • “Sustained Clinical Remissions: Toward a Two-Step Program”, April 2017 Newsletter, p. 4-7

Clinical Trials

  • “Cancer Drugs Approved Too Rapidly — Expert Review”, June 2016 Newsletter, p. 4-6
  • Clinical trials and radiation exposure, Article #5, p.33
  • Pros and cons of participation in clinical trials, Article #7, p. 31-34

CLA , December 2015 Newsletter, p. 19-20; March 2015 Newsletter, p. 17-18

CLL (Chronic Lymphocytic Leukemia) , December 2013 Newsletter, p. 23

C-Reactive Protein (CRP)

  • Extensive review of the research linking CRP to inflammation and follicular lymphoma, August 2022 Newsletter, p. 6-17
  • General information: mid-July 2020 Newsletter, p. 1-4

Coffee, October 2017 Newsletter, p. 15-16; October 2022 Newsletter, p. 8-9

Colostrum

  • Update for 2024, May 2024 Newsletter, p. 6-8
  • “Colostrum May Help with Compromised Immunity and Chemo Damage”, April 2017 Newsletter, p. 13-17
  •  Article #7, p. 29

CoEnzyme Q-10

  • Update on CoQ-10 supplements,  June 2022 Newsletter, p. 18-19
  • September 2015 Newsletter, p. 24-26
  • Recommendation for CoEnzyme Q10 during treatment with R-CHOP, Article #8, p.14

Coleman, Dr. Morton

  • Commentary on maintenance rituximab from a prominent lymphoma specialist, March 2019 Newsletter, p. 8-9; September 2012 Newsletter, p. 5

Collagen

  • “Cell Growth Supplements that  MUST be Avoided”,  September 2024 Newsletter, p. 10-15
  • Gelatin is a source of natural collagen, October 2023 Newsletter, p. 11-18
  • All about collagen, February 2023 Mid Month Newsletter, p. 1-7

Consultation Guidelines

  •  “Personal Guidance” tab on the top left area of this webpage
  •  “Should I Choose Treatment or Try the “Natural” Route?”, February 2014 Newsletter, p. 13-17

Coronavirus (COVID-19)

  • The Four Pillar (4PEP) Program and COVID-19, February 2022 Newsletter, p. 2-15
  • “COVID Data for Lymphoma Patients”,  January 2022 Mid Month Newsletter, p. 2-12
  • “The One Factor that Combats both Viruses and Lymphoma”,  September 2021 Mid Month Newsletter, p. 1-13
  • “The Pandemic and the Sleep Pillar”,  May 2021 Mid Month Newsletter, p. 1-11
  • “COVID-19? Prominent New Research Supports Vitamin D”,  mid-September 2020 Newsletter, p. 1-9
  • “Expert Recommendations re Vaccine and Therapy for Indolent Lymphoma During the COVID-19 Pandemic”,  March 2021 Newsletter, p. 2-11
  • “COVID-19 Risk Reduction Natural Strategies”,  February 2021 Mid Month Newsletter, p. 1-13
  • “COVID-19: A Healthy Gut Microbiome is an Essential Defense”, January 2021 Mid Month Newsletter, p. 1-13
  • “Coronavirus COVID-19 Update Specific to Lymphoma”,  April 2020 Newsletter (entire); mid-April 2020 Newsletter (entire);  Update on these items, May 2020 Newsletter, p. 3-9 and mid-May Newsletter, p. 1-10

Cosmetic Concerns, Article #6, p. 7-8 ; Article #7, p. 35-36

CPOP, Article #6, p.27

Cranberry Juice, October 2023 Newsletter, p.9; January 2018 Newsletter, p. 12-15

CRISPR, October 2016 Newsletter, p. 14-15; December 2016 Newsletter, p. 25-26

CT Scans (see Scans)

Curcumin

  • “Curcumin to Reduce Inflammation”, March 2017 Newsletter, p. 9-10
  • “Newly identified Benefit of Curcumin”, November 2014 Newsletter, p. 16-19
  • Curcumin may help stimulate FOXP3+ Treg production in the bowel, June 2017 Newsletter, p. 14-15
  • Epigenetic benefits of turmeric and curcumin, Article #11, p.17-18
  • Bioavailability of curcumin, October 2016 Newsletter, p. 20-21; September 2015 Newsletter, p. 22-24
  • Curcumin and bowel inflammation, October 2016 Newsletter, p. 7-8; September 2015 Newsletter, p. 22-24
  • Curcumin absorption and need to add to a fat, October 2006 Newsletter, p. 12-14

Cure

  • “New Data Suggests Follicular Lymphoma May Be Curable”,  February 2020 Newsletter, p. 20-21
  • Durable cure for fNHL not possible without correction of the underlying genetics, December 2015 Newsletter, p. 3-7;  March 2014 Newsletter, p. 9-10

Cyclophosphamide (Cy), Article #6, p.20

[return to top ]

______________________________________

D

Dairy Products, June 2021 Newsletter (goat milk), p. 13-17; June 2016 Newsletter, p. 13-15; April 2015 Newsletter, p. 21-23

Dental Problems  and fNHL, January 2020 Newsletter, p. 13-15; June 2018 Newsletter, p. 4-8; October 2017 Newsletter, p. 14-15; June 2015 Newsletter, p. 14-15; April 2013 Newsletter, p. 14; Article #7, p. 6-7

Diagnosis

  • “Guidance for the Newly Diagnosed Survivor”, May 2021 Newsletter, p. 1-19
  • Need-to-know information at the time of diagnosis, Article #1 (all); Article #5,  p. 5-18; February 2018 Newsletter, p. 3-9
  • “An Urgent Need to Refine and Implement Available New Testing Procedures for fNHL”,  November 2018 Newsletter, p. 4-9
  • Determining stage and grade and the time of diagnosis, Article #5, p. 7-8
  • Next-generation sequencing blood test for cancer detection, June 2020 Newsletter, p. 12-14
  • “New Developments in Cancer Detection”, December 2018 Newsletter, p. 18-19
  • Problems associated with diagnosing transformation, Article #4, p. 6-8
  • General diagnosis information, Article #5, p. 5-18; Article #2, p. 9-13, 31-34
  • Obtaining the correct diagnosis, Article #5, p. 9-11
  • Common sub-groups of patients at time of initial diagnosis, Article #5, p. 5-7
  • Lack of concurrence in diagnosis, Article #5, p. 9
  • Circulating tumor DNA test (ctDNA), Article #2, p. 30
  • Biopsies and diagnosis, Article #5, p. 10-11
  • Composite histology, Article #5, p. 10
  • Discordant histology, Article #5, p.10
  • Low and high tumor burden at the time of diagnosis, Article #5, p. 11-12
  • Risks of deferring treatment at the time of diagnosis, Article #5, p. 15-16
  • Important biomarkers in pathology reports at the time of diagnosis, Article #5, p. 16-18
  • Bone marrow biopsies, Article #5, p. 10-11
  • Variable pathology within and between nodes complicates diagnosis and treatment decisions, December 2013 Newsletter, p. 12-14
  • FOXP3 biomarker as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13

Double-Hit Lymphoma , April 2022 Newsletter, p. 16-17; Article #5, p.36;  September 2014 Newsletter, p. 9-11

DNA Repair Genes

  • Description of DNA repair genes and their importance for holding fNHL in check, August 2015 Newsletter, p. 12
  • DNA repair genes more effective with quality sleep, January 2020 Newsletter, p. 9-12

Drug Development (New)

  • “Better Drugs in the Pipeline?”, August 2019 Newsletter, p. 11-13; May 2019 Newsletter, p. 16
  • “Cancer Drugs Approved Too Rapidly — Expert Review”, June 2016 Newsletter, p. 4-6
  • “New Drugs:  Careful Assessment Required”, January 2016 Newsletter, p. 9-10
  • “T-Cell Immunotherapy: Promising or Playing with Fire?”,  February 2017 Newsletter, p. 11-13
  • New treatments without long-term trial results (updated to October 2017), Article #6, 28-35
  • Falsified data in clinical trials,  November 2017 Newsletter, p. 13-15
  • New drugs and the challenge of “precision medicine”,  Article #5, p. 36-38
  • “Improvements to Rituximab — No NOT GAZYVA Obinutuzumab”,  November 2016 Newsletter, p. 13-14
  • Trial results with new kinase drugs Imbruvica and Idelalisib with relapsed indolent or follicular lymphoma, January 2014 Newsletter, p. 12-16
  • The rising cost of new cancer drugs creates “financial toxicity” for follicular lymphoma survivors, November 2015 Newsletter, p. 12-15
  • “The Cancer Industry is Going Through a Re-make”, April 2015 Newsletter, p. 11-14
  • The fundamental dilemma faced by the new genetic-based drugs, Article #6, 28-32; October 2014 Newsletter, p. 17-21
  • Ibrutinib clinical trials with follicular lymphoma, September 2013 Newsletter, p. 3-13
  • List and discussion of new drugs under development for fNHL, Article #6, p. 28-34; July 2013 Newsletter, p. 17-19

Dynamic Observation

  • “Watch and Wait: Maintenance Rituximab … Latest Expert Opinions”, November 2011 Newsletter, p. 2-5
  • As a viable option for pro-active, newly diagnosed patients, May 2009 Newsletter, p. 14-15
  • How to monitor progress during periods of dynamic observation, Article #7. p. 8-11
  • Risks of deferring treatment at the time of diagnosis, Article #5, p. 15-16

[ return to top ]

_____________________________________________

E

Eggs

  • Immune cells need choline, high in eggs, March 2019 Newsletter, p. 14-16

Elderberry,  August 2021 Mid Month Newsletter, p. 2-8

Ellagic Acid

  • Epigenetic anti-cancer effects of ellagic acid, Article #10, p. 25-26; Article #11, p. 6; October 2016 Newsletter, p. 13
  • Ellagic acid may block blood vessel formation in tumors, Article #10, p. 25-26
  • Ellagic acid’s role in preventing angiogenesis, Article #10, p. 25-26

Environmental Toxins

  • Even low doses of glyphosate in foods can be toxic, September 2023 Newsletter, p. 7-13
  • Tap water safety and lymphoma survival, April 2023 Newsletter, p. 3-8
  • Environmental Toxins as a barrier to long term survival with follicular lymphoma, March 2023 Mid Month Newsletter, p. 2-12
  • “Microplastics and Their Association with Lymphoma”, May 2022 Newsletter, p. 11-17
  • 2022 update on glyphosate (a.k.a. Roundup) in foods, with emphasis on its impact on the gut microbiome, and bisphenols, March 2022 Newsletter, p. 2-16
  • “Unsuspected Toxins Harm the Gut Microbiome”,  March 2021 Newsletter, p. 12-20
  • Human studies show many toxins can be cleared quickly from the body, March 2019 Newsletter, p.14-21
  • “Recommended Ways to Minimize Common Toxins”, March 2020 Newsletter, p. 8-16
  • “Glyphosate/Roundup — New Concerns with Food”, July 2019 Newsletter, p. 7-15
  • “Toxins in Seafood: Concerns But Good Choices Too”, February 2019 Newsletter, p. 6-13
  • “Toxic Chemicals in Food Packaging”, September 2018 Newsletter, p. 16-19
  • “Toxic Exposures and Non-Hodgkins Lymphoma”,  May 2017 Newsletter, p. 4-15
  • “Counteracting Cancer-Causing Toxins with Natural Strategies”, September 2016 Newsletter, p. 4-12
  • “Relentless Concerns with Roundup”, August 2018 Newsletter, p. 17-18
  • Roundup weedkiller (glyphosate) linked with follicular lymphoma, May 2015 Newsletter, p. 16-19
  • Bisphenol A (BPA) is linked to overexpression of gene EZH2, a key epigenetic driver of follicular lymphoma, January 2016 Newsletter, p. 7-8
  • “Artificial Turf Fields Linked to Lymphoma”, April 2016 Newsletter, p. 10-12
  • Cancer-promoting environmental toxins associated with follicular lymphoma, Article #11, p. 6-7; August 2018 Newsletter, p. 6-7

Epigenetics

  • Article #11: “Epigenetic Regulators of Follicular Lymphoma: A Reference Guide”, linking the latest in cancer-related epigenetic research to key anti-cancer lifestyle strategies
  • Article #10: “Getting Follicular Lymphoma Cells to Die on Their Own”, detailed examination of new epigenetic research applied to follicular lymphoma
  • Article #3 — Why epigenetics is the basis for the 4PEP program, p. 15-22
  • “Research Breakthrough for Follicular Lymphoma Survivors”, November 2022 Mid Month Newsletter, p. 1-6
  • “Gearing Up for the New Era”,  January 2021 Newsletter, p. 1-16
  • “Personalized Health: New Thinking for the New Era”, February 2021 Newsletter, p. 2-13
  • Link to video explaining epigenetics, Article #3,  p. 22
  • “How Healthy Normal Cells Defeat Follicular Lymphoma”, February 2017 Newsletter, p.  4-8
  • “Normal Cells Cure Cancer”, July 2016 Newsletter, p. 3-10
  • The epigenome as a “wildcard” in the management of follicular lymphoma, November 2015 Newsletter, p. 7-8
  • “A Closer Look at Preventing New Tumors”,  May 2016 Newsletter, p. 15-20
  • Managing tumor suppressor gene PTEN with nanotechnology and/or diet, October 2018 Newsletter, p. 7-10
  • Epigenetic Age Predicts Cancer”, March 2016 Newsletter, p.24
  • Detailed table listing the epigenetic gene remediation properties of individual strategies in the 4PEP program, October 2015 Newsletter, p. 22-23
  • DNA repair genes and tumor suppressor genes are our “friends” and oncogenes are our “enemies”, and the epigenome mediates between them, February 2016 Newsletter, p. 7-13
  • “Cancer 2015 … A New Era Unfolds”, July 2015 Newsletter, p. 5-10
  • Diagram depicting role of lifestyle, the epigenome and the genome as interrelated factors in cancer progression and regression, August 2015 Newsletter, p. 14-15
  • Epigenetics and natural regression of follicular lymphoma, Article #11, p. 21-22
  • “Emotional Well Being Linked to Gene Expression”, April 2016 Newsletter, p. 15-17
  • Medical experts explain the power of epigenetics in two important videos, February 2015 Newsletter, p. 11
  • The Roadmap Epigenomics Program, March 2015 Newsletter, p. 6-8
  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • Concerns with genetic-based drugs for follicular lymphoma targeting single genes, September 2013 Newsletter, p. 3-13
  • Ringleader fNHL genes and enzymes and lifestyle strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-15
  • Epigenetics researcher Dr. Dean Ornish finds major shifts in gene expression in cancer patients participating in a 3 month program of lifestyle changes, Article #10, p. 4-6; July 2008 Newsletter, p. 3-6
  • “Let the Cancer Cells Die On Their Own”, July 2010 Newsletter, p. 10-13

Emulsifiers,  January 2017 Newsletter, p. 23

Endocrine Disruptors February 2020 Newsletter, p. 15-17 (BPA,BPS)

Exercise

  • “Breakthrough Research Finds Brief Exercise Activates T Cells in Lymphoma Patients”,  October 2024 Newsletter, p. 3-10
  • Exercise and T Cells,  September 2022 Newsletter, p. 7-8
  • Exercise as an important natural strategy, Article #3, p. 35-44; Article #7,  31-32; April 2018 Newsletter, p. 14-17; July 2015 Newsletter, p.12-17
  • “Four Reasons Lymphoma Survivors Need Exercise”, September 2020 Newsletter, p.3-8
  • “How Exercise Can Help Prevent Relapse”, October 2019 Newsletter, p. 13-19
  • Exercise during chemotherapy, Article #8 p. 19-20; Article #9, p. 8-9; November 2014 Newsletter, p. 14-16
  • Epigenetic anti-cancer effects of exercise, Article #10, p. 16-19; Article #11, p. 7-8;  Article #7, p.36-38; March 2015 Newsletter, p. 15-16
  • “The Daily Double: Where the Gold is Buried”, April 2012 Newsletter, p. 3-6
  • How exercise can purify the lymph fluid, May 2014 Newsletter, p. 6-7; Article #7, p. 37-38, Article #3, p. 35
  • Exercise strategy to enhance Natural Killer (NK) immune cells, December 2019 Newsletter, p. 12-16
  • Enzyme AMPK, generated through exercise, found to restrict lymphoma cell growth, Article #10, p. 17-19; Article #11, p.8-9; February 2013 Newsletter, p. 10-12
  • The importance of daily movement to lymphatic system health, January 2013 Newsletter, p. 9-11
  • Long walks and hikes may contribute to increasing levels of oxygen in the blood, healthy sweat and lymph purification, and slowing cancer growth rates, December 2018 Newsletter, p. 11-15; September 2014 Newsletter, p. 17-19; Article #10, p. 8-10; January 2014 Newsletter, p. 10-12; July 2013 Newsletter, p. 7-15; May 2013 Newsletter, p. 19-20; Article #3, p.39
  • Exercise as an important natural strategy, Article #7, p. 31-32;  Article #3, p. 35-44; April 2018 Newsletter, p. 14-17; July 2015 Newsletter, p.12-17
  • Physical activity associated with higher overall survival in cancer patients,  May 2017 Newsletter, p. 17-19
  • Research on cancer and exercise
    • Mayo Clinic research links higher levels of physical activity to increased overall survival with lymphoma, January 2018 Newsletter, p. 8-11  
    • Study finds that light, regular exercise positively effects the expression of over 7000 genes, September 2013 Newsletter, p. 18

Exosomes, September 2019 Newsletter, p. 4; September 2014 Newsletter, p. 13-14

EZH2 (gene)  

  • Follicular lymphoma survivors with a mutated EZH2 gene at diagnosis — implications for taking R-CHOP vs. R-Bendamustine, October 2022 Mid Month Newsletter, p. 2-6
  • Gene EZH2 , a key epigenetic regulator of follicular lymphoma, overactivated when exposed to bisphenol A (BPA), March 2022 Newsletter, p. 11-12; September 2017 Newsletter, p.4-11; January 2016 Newsletter, p. 4-6; September 2016 Newsletter, p.5
  • Epigenetic drug Tazemetostat targets EZH2, Article #6, p. 30-31
  • Natural strategies to “tame” the overexpression of EZH2, December 2016 Newsletter, p. 7-8:  January 2016 Newsletter, p. 7-8
  • Gene EZH2 identified as one of the 7 most important genes in the m7-FLIPI  research published in 2015, September 2015 Newsletter p. 4-6; 10-14.

[ return to top ]

__________________________________________________

F

Fasting Strategy, October 2018 Newsletter, p. 10-13; December 2012 Newsletter, p. 3-6; November 2012 Newsletter, p. 6-7 and p. 14-15

Fats

  • “Why Good Fats are Extra Important to Combat Follicular Lymphoma”, December 2015 Newsletter, p. 20-21;  March 2017 Newsletter, p. 7-8; November 2014 Newsletter, p. 10-13

Fermented Foods , May 2024 Newsletter, p. 5-6; August 2022 Newsletter, p. 16-17

Fiber

  • “Fiber: Reinforcing 2019’s Best Cancer Research”, November 2019 Newsletter, p. 10-15
  • Butyrate, dietary fiber and the tumor microbiome, October 2020 Newsletter, p. 11-12; September 2019 Newsletter, p. 5-13
  • “Dietary Fiber is Essential for Follicular Lymphoma Survivors”,  July 2017 Newsletter, p. 19-23
  • General information:  October 2016 Newsletter, p. 10-11, March 2017 Newsletter, p. 11-13; December 2016 Newsletter, p. 23-24

Fish Oil

  • “Omega 3s: Update on a Vital Nutritional Factor”, September 2021 Newsletter, p. 2-17
  • Clear out the chemo debris to optimize the eradication phase (fish oil and resolvins), October 2021 Newsletter, p. 14-18
  • Epigenetic anti-cancer effects of fish oil, September 2015 Newsletter, p. 21-22; Article #11, p. 11-12
  • Supplementation before and during chemotherapy, Article #8, p. 6-7 & 12-13; September 2021 Newsletter, p. 9-13; February 2020 Newsletter, p. 10-11; April 2018 Newsletter, p. 4-7

FLIPI score

  • FLIPI and FLIPI 2, strengths and weaknesses as prognostic assessment tool, Article #2, p. 29-31
  • “FLIPI: How Valid?” , June 2014 Newsletter, p. 8-11
  • FLIPI score at the time of diagnosis, Article #5, p. 12-14
  • m7-FLIPI as a potentially new and better forecasting tool, Article #5, p. 14-15; September 2015 Newsletter, p. 4-6; 10-14; Article #2, p. 33

Fludarabine

  • Study shows R-Fludarabine regimen unsafe and not recommended for an upfront therapy for fNHL, November 2011 Newsletter, p. 11-13
  • “Major Caution re Fludarabine”, November 2010 Newsletter, p. 12-13
  • General information, Article #6, p. 20, August 2012 Newsletter, p. 12-13

Follicular Lymphoma

  • “The Time-Tested Plan to PREVENT Follicular Lymphoma Relapse”, July 2024 Newsletter, p. 2-16
  • “Moving Ahead with New Knowledge Toward a Working Cure for Follicular Lymphoma”,  December 2023 Newsletter, p.3-14
  • “Follicular Lymphoma Survival 35 Years”,  July 2023 Mid Month Newsletter, p. 1-17
  • ” Relapse Warning Signs — What to Do”,  July 2023 Newsletter, p. 3-19
  • “Is Relapse Inevitable?”,  June 2023 Mid Month Newsletter, p. 1-9
  • Barriers that Block Progress with Follicular Lymphoma Part 2: Environmental Toxins, March 2023 Mid Month Newsletter, p.2-12
  • Barriers that Block Progress with Follicular Lymphoma Part 1 (lack of clean air and water, poor diet, sleep deprivation, hidden infection),  March 2023 Newsletter, p. 2-12
  • Follicular lymphoma with bone involvement, April 2024 Newsletter, p. 11-12
  • Unique perspectives on the connections between the gut microbiome and follicular lymphoma, February 2023 Newsletter, p. 5-7
  • “Scanning Savvy (update to January 2023), January 2023 Newsletter, p. 2-14
  • “Follicular Lymphoma: Toward a Working Cure — Perspectives from a 34-year Survivor”, November 2022 Newsletter (entire)
  • “Follicular Lymphoma: Ten Essential Strategies to Achieve a Working Cure”, December 2022 Newlsetter (entire)
  • “Follicular Lymphoma — Winning the T Cell Game”,  September 2022 Newsletter, p.3-14
  • “Follicular Lymphoma — Understanding Inflammation”, August 2022 Newsletter, p. 6-17 
  • “Lymphoma Survival Insights — Epigenetics, Microbiomes and Inflammation”,  August 2022 Newsletter, p. 2-6
  • “Indolent Lymphoma Insight 2022”,  June 2022 Mid Month Newsletter, p. 1-5
  • “Follicular Lymphoma Relapse — Things to Know, What to Do” April 2022 Newsletter, p. 2-21
  • “Follicular Lymphoma Update and Developments for 2021”, December 2021 Newsletter, p. 2-9
  • “The One Factor that Combats both Viruses and Lymphoma”,  September 2021 Mid Month Newsletter, p. 1-13
  • “The Liver, Bile, Bile Acids, Gut Bacteria and Lymphoma”, July 2021 Newsletter, p. 3-12
  • “The Eradication Phase”,  June 2021 Newsletter, p. 2-12
  • “Guidance for the Newly Diagnosed Survivor”,  May 2021 Newsletter, p. 1-19
  • “Natural Regression — Update on an Achievable Miracle”, October 2020 Newsletter, p. 4-15
  • “Gearing Up for the New Era”, January 2021 Newsletter, p. 1-16
  • “Personalized Health: New Thinking for the New Era”, February 2021 Newsletter,  p. 2-13
  • Details re the Eradication–Rejuvenation approach for fNHL survivors, December 2020 Newsletter, p. 2-6
  • “A Perfect Treatment is Only Part Way There”, August 2020 Newsletter, p. 10-12
  • ” 32 Years After Diagnosis: Eradication — Rejuvenation”,  July 2020 Newsletter,  p. 3-9
  • “Latest Research on Follicular Lymphoma: Stunned Silence”; September 2018 Newsletter, p. 3-8
  • “Advancements in Research toward Achieving 30 Years of Healthy Survival with Follicular Lymphoma”,  October 2017 Newsletter,  p. 2-10
  • “Follicular Lymphoma — Different People, Different Approaches, Different Outcomes”, March 2020 Newsletter, p. 2-5
  • “Toxic Exposures and Non-Hodgkins Lymphoma”,  May 2017 Newsletter, p. 4-15
  • “Rapid Nodal Growth”, August 2018 Newsletter, p. 3-11
  • “Risk Factors Associated with Follicular Lymphoma”, March 2017 Newsletter, p. 3-7
  • “Follicular Lymphoma and Infections: Hidden, Active and Inflammation”, October 2018 Newsletter, p. 14-17
  • “The Development and Resolution of Follicular Lymphoma”, January 2017 Newsletter, p. 3-4
  • “Follicular Lymphoma 2016: A Rapidly Shifting Landscape”, January 2016 Newsletter, p. 17-20
  • “How Healthy Normal Cells Defeat Follicular Lymphoma”, February 2017 Newsletter, p.  4-8
  •  Winning the follicular lymphoma challenge  — the need to understand the “genetic fact” , December 2015 Newsletter, p. 3-7
  • “First Node in the Head or Neck Region”, June 2018 Newsletter, p. 4-8
  •  “Which is worse, enlarged nodes or new nodes?”, September 2015 Newsletter, p. 17-20
  • “The Development and Resolution of Follicular Lymphoma”, June 2015 Newsletter, p. 5-8
  • “Beating Follicular Lymphoma is a Two-Step Process”, March 2015 Newsletter, p. 4-6 
  • “New Developments in Diagnosing Follicular Lymphoma”, December 2014 Newsletter, p. 12-15
  • “20+ Strategic Errors in Managing Follicular Lymphoma”, December 2014 Newsletter, p. 4-11
  • “OK Doc, Why Did I Get Follicular Lymphoma?”, November 2014 Newsletter, p. 6-9
  • “Why Nodes Grow and Why They Shrink”, March 2013 Newsletter, p. 2-6
  • “Purify my Lymph Fluid”, May 2014 Newsletter, p. 6-7
  • High and low risk categorization for fNHL patients with m7-FLIPI, September 2015 Newsletter, p. 7-9
  • How to measure progress with fNHL, Article #7, p. 8-11
  • The stages of progress in regression and resolution of fNHL, August 2015 Newsletter, p. 16-18
  • Why follicular lymphoma cells are more susceptible to dying on their own as compared to other types of malignant cells, Article #10, p. 7
  • “The Way Ahead … The Research We Really Need”, February 2013 Newsletter, p. 17-20
  • Research outlook … “the big picture”, July 2013 Newsletter, p. 24-28
  • “Bad luck”, good fortune, and the origins of follicular lymphoma, February 2015 Newsletter, p. 4-9
  • New paradigm for managing follicular lymphoma, Article #2, p. 4-6
  • Follicular lymphoma in young adults, June 2014 Newsletter, p. 11-12
  • “Does Follicular Lymphoma Spread to Other Organs?”, May 2013 Newsletter, p. 11
  • When to treat, Article #6 p. 4-10
  • Incidence rates, Article #2, p. 23-25
  • Explaining predicted survival and survival statistics, Article #2, p.25-29
  • The development and progression of follicular lymphoma (overview), Article #2, p 4-8
  • Stanford research on overall survival (OS) , Article #2, p. 26-29

Foods to Avoid

  • Even low doses of glyphosate in foods can be toxic, September 2023 Newsletter, p. 7-13
  • Need for fNHL patients to avoid whey protein powder, glutamine supplements, and protein powder supplements, Article #7, p. 43-44;  Article #3, p. 14 and 67-68
  • Need for fNHL patients to avoid supplementation with glutamine, Article #11, p. 9-10
  • Milk and its pro-inflammatory properties, June 2016 Newsletter, p. 13-15
  • Pitfalls of flour, sugar and bread for cancer survivors, November 2013 Newsletter, p. 11-13
  • Lists of foods to avoid, Article #3, p. 67-68
  • Don’t feed the bad dog, June 2018 Newsletter, p. 9-12

Forest Therapy 

  • Research links the practice of forest bathing to increased NK cell activity,  March 2024 Newsletter, p. 14-18

Four Pillar Approach

  • Prioritizing the four pillars, Article #10, p. 15-18

FOXP3 Biomarker

  • FOXP3, a potent prognostic indicator of long-term survival with fNHL, increases dramatically with both sunlight exposure and the presence of retinoic acid, June 2017 Newsletter, p. 10-15
  • FOXP3 as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13, Article #5, p. 17-18

[ return to top ]

____________________________________________________________

G

Gazyva (Obinutuzumab, Gazyvaro)

  • Research links treatment with rituximab and obinutuzumab to low Ig levels (hypogam),  July 2022 Newsletter, p. 8-12 
  • “Gazyva (Obinutuzumab) vs. Rituximab — Surprises to be Aware Of”, September 2019 Newsletter, p. 13-16
  • “Latest Gazyva Obinutuzumab Data”, January 2017 Newsletter, p. 19-22
  • General Information, Article #6, p. 21
  • “Gazyva Obinutuzumab as a Replacement for Rituximab: What Can We Expect?”, May 2016 Newsletter, p. 3-14
  • “Improvements to Rituximab — No NOT GAZYVA Obinutuzumab”,  November 2016 Newsletter, p. 13-14
  • Side effects of Gazyva, May 2016 Newsletter, p. 6-8; 12-13
  • Gazyva follicular lymphoma clinical trial results alone and in combination with other drugs, May 2016 Newsletter, p. 3-14; March 2015 Newsletter, p. 12-15

GEM-P, Article #6, p.27

GEMOX, Article #6, p.27

Gene Profiling and Diagnostic Testing

  • m7-FLIPI and risk profiling at the time of diagnosis, Article #5, p. 14-15
  • Follicular lymphoma risk assessment test developed based on the gene expression levels of 23 genes, May 2018 Newsletter, p. 15-17
  • Genetic test developed based on m7 research that helps to predict treatment effectiveness, February 2020 Newsletter, p.17-19
  • “Newly Diagnosed Follicular Lymphoma — To Treat or Not? New Genetic Test Provides Statistical Data to Help Guide the Decision”, September 2016 Newsletter, p. 17-19
  • Circulating tumor DNA (ctDNA) test, Article #2, p. 30; Article #5, p.35-36; November 2016 Newsletter, p. 4-5
  • “Latest Genetic Data Predicts Follicular Lymphoma Transformation”,  September 2016 Newsletter, p. 20-22
  • Follicular lymphoma — testing for mutated genes with m7-FLIPI, Article #5, p. 14-15; September 2015 Newsletter, p. 4-16
  • New directions in genetic testing — implications for cancer patients, Article #5, 34-38; May 2015 Newsletter, p. 7-12
  • FoundationOne Heme (diagnostic genetic test for blood cancers), March 2015 Newsletter, p. 9-12
  • “Genetic Testing… Results Reinforce Importance of Lifestyle Choices”, April 2015 Newsletter, p. 9-11

Genetic Research 

  • “Latest Research on Follicular Lymphoma: Stunned Silence”; September 2018 Newsletter, p. 3-8
  • “An Urgent Need to Refine and Implement Available New Testing Procedures for fNHL”,  November 2018 Newsletter, p. 4-9
  • m7-FLIPI and risk profiling at the time of diagnosis, Article #5, p. 14-15
  • Gene SESTRIN1 frequently missing or malfunctioning in fNHL patients, July 2017 Newsletter, p. 17-19
  • Leading researchers find under and over-expressed “out of balance” genes in the epigenome are a “pivotal hallmark” of follicular lymphoma, January 2016 Newsletter, p. 17-20
  • Mutations,translocations and the role of the epigenome — we are moving toward a more sophisticated understanding of how follicular lymphoma develops and how natural regression can occur, November 2015 Newsletter, p. 5-7
  • “Repairing Mutations? Inheritance? New Grading System?”, June 2015 Newsletter, p. 8-11
  • Diagram depicting role of lifestyle, the epigenome and the genome as interrelated factors in cancer progression and regression, August 2015 Newsletter, p. 14-15
  • Gene MMP-9 , stress, and follicular lymphoma, December 2014 Newsletter, p. 17-23
  • Gene CDKN2A status predicts overall survival time for patients treated with rituximab, April 2015 Newsletter, p. 5-7
  • Gene MLH1 status can block response to CHOP, April 2015 Newsletter, p. 7-9
  • Genetic profiles as prognostic indicators for long-term survival, January 2015 Newsletter, p. 5-7; January 2014 Newsletter, p. 8-9: October 2013 Newsletter, p. 2-6
  • “New Developments in Diagnosing Follicular Lymphoma” , December 2014 Newsletter, p. 12-15
  • “The Genes Driving Follicular Lymphoma and Those that Can Reverse It”, January 2014 Newsletter, p. 3-9
  • Genetic research and new research findings re transformation, Article #4, p. 15-23; Article #5, p. 14-15; 34-38
  • Genes associated with follicular lymphoma transformation, Article #4, p. 15-23; June 2014 Newsletter, p. 4-8
  • Review of genetic testing issues and new drug development, Article #5, p. 34-38
  • DNA repair genes and their role in managing follicular lymphoma, January 2014 Newsletter, p. 7-8
  • A third cancer management paradigm is emerging which is beginning to match lifestyle strategies with the epigenetic remediation of key ringleader genes driving cancer, Article #11, p. 1-24; Article #2, p. 4-6; November 2013 Newsletter, p. 3-6
  • Epigenetic anticancer effects of the 4PEP program: Article #3: Article #10; Article #11
  • Ringleader genes in fNHL and their effect on epigenetic expression, October 2013 Newsletter, p. 3-6: Article #11, p. 1-24; February 2013 Newsletter, p. 2-15
  • Epigenetics and natural regression of follicular lymphoma, Article #11, p. 20-23
  • Myc gene, a suspected ringleader gene driving fNHL, linked to glutamine, February 2013 Newsletter, p. 8-9; December 2012 Newsletter, p. 10-13
  • Lymphoma genetic profile completed, September 2012 Newsletter, p. 8-10
  • Gene MLL2 (KMT2D), connected to histone action, is discovered to be mutated and rendered inactive in 89% of newly diagnosed fNHL patients, January 2014 Newsletter, p. 5-7; October 2013 Newsletter, p. 3-6
  • Gene P53 and selenium supplementation, Article #11, p. 14-15

Gerson therapy, Article #7, p. 50-51

Ginger

  • December 2015 Newsletter, p. 8-9
  • Epigenetic anticancer effects of ginger, Article #11, p.8
  • Ginger’s role in bowel health,  October 2016 Newsletter, p. 6-7
  • Ginger and exosomes, September 2019 Newsletter, p. 4;  June 2015 Newsletter, p. 20-21: September 2014 Newsletter, p. 13-14
  • Ginger used to combat nausea during chemotherapy, June 2015 Newsletter, p. 19-20

Glucose Deprivation

  • Surprisingly dissimilar results found for effects of carbohydrate-rich foods on individuals, January 2016 Newsletter, p. 11-16
  • Epigenetic anti-cancer effects of glucose deprivation, Article #10, p. 22-24; Article #11, p. 9
  • Supplements known to affect blood glucose levels, April 2013 Newsletter, p. 7-9
  • Dietary challenges in reducing sugar in the diet, January 2013 Newsletter, p. 5-9
  • Cinnamon found to help with glycaemic control, February 2013 Newsletter, p. 17-18
  • Practicing glucose deprivation as part of a daily program, July 2013 Newsletter, p. 8-10

Glutamine

  • “Cell Growth Supplements that  MUST be Avoided”,  September 2024 Newsletter, p. 10-15
  • Potentially harmful epigenetic effects of glutamine supplements and glutamates, Article #10, p. 26-27; Article #11, p. 9-10; March 2014 Newsletter, p. 14-15
  • Research shows glutamine promotes tumor growth in hypoxic conditions, March 2014 Newsletter, p. 14-15
  • Glutamine supplementation (including protein powders) as a possible trigger of transformation, Article #4, p. 14
  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • Glutamine supplementation to be avoided as it is a key source of fuel for cancer cells,  Article #10, p. 26-27; Article #11, p. 9-10; Article #7, p.43-44 

Glycine

  • Gelatin is a natural source of glycine,  October 2023 Newsletter, p. 11-18
  • Also see June 2012 Newsletter, p. 17-19; July 2019 Newsletter, p. 11-13; July 2021 Newsletter, p. 8-9; August 2021 Newsletter, p. 5-7

Glyphosate (Roundup)

  • Even low doses of glyphosate in foods can be toxic, September 2023 Newsletter, p. 7-13
  • 2022 update on glyphosate in foods, with emphasis on its impact on the gut microbiome, March 2022 Newsletter, p. 2-9
  • “Glyphosate: Lifesaving New Data”, August 2021 Newsletter, p. 3-10
  • “Glyphosate/Roundup — New Concerns with Food”, July 2019 Newsletter, p. 7-15
  • Glyphosate and genetically modified foods, February 2019 Newsletter, p. 15-18
  • Glyphosate and the gut microbiome, July 2019 Newsletter, p. 10-13; February 2019 Newsletter, p. 17-18
  • “Relentless Concerns with Roundup”, August 2018 Newsletter, p. 17-18
  • Glyphosate and toxic exposure risks, July 2019 Newsletter, p. 7-17; May 2017 Newsletter, p. 5-7
  • Roundup weedkiller (glyphosate) classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19

GMO (Genetically Modified) Foods

  • “Do GM Foods Disrupt the Human Gut?”,  February 2019 Newsletter, p. 14-21
  • GMO foods and risk factors for cancer patients, August 2014 Newsletter, p. 24-25; May 2014 Newsletter, p. 8-10

Grades of Follicular Lymphoma, Article #2, p. 14-15; Article #5, p. 7-8

Grade 3 fNHL

  • “Grades 3A and 3B: Latest Essential Information”, December 2010 Newsletter, p. 13-15
  • General information: Article #2, p. 11-13

Gut Microbiome (see Microbiome)

[ return to top ]

_____________________________________________________

H

H Pylori bacteria, February 2007 Newsletter, p. 7

Hemoglobin

  • Hemoglobin blood test reading– what it mean for lymphoma survivors, March 2022 Mid Month Newsletter, p. 3-12
  • As a major indication of transformation, August 2008 Newsletter, p. 7-8; Article #2, p.34
  • Interpreting hemoglobin levels in blood tests, October 2014 Newsletter, p. 5-12; Article #5, p. 22-23

Herbicides and Pesticides

  • Even low doses of glyphosate in foods can be toxic, September 2023 Newsletter, p. 7-13
  • 2022 update on glyphosate in foods, with emphasis on its impact on the gut microbiome, March 2022 Newsletter, p. 2-9
  • As a risk factor for lymphoma, May 2017 Newsletter, p. 5-9: Article #11, p.6-7; Article #3, p. 76
  • “Glyphosate/Roundup — New Concerns with Food”, July 2019 Newsletter, p. 7-15
  • Many pesticides can be cleared quickly from the body with all organic diet, March 2019 Newsletter, p.17-18
  • Studies linking pesticide exposure with lymphoma, May 2017 Newsletter 5-9
  • Roundup weedkiller (glyphosate) classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19
  • Use of glyphosate, 2,4-D, Atrazine, and Dicamba, all associated with fNHL, is increasing, May 2017 Newsletter, p. 5-9
  • Pesticide residues in fruits and vegetables, October 2013 Newsletter, p. 9-13
  • Links to lists of fruits and vegetables with lowest and highest amounts of pesticides, June 2016 Newsletter, p. 16-17
  • Natural weed killer formula, April 2007 Newsletter, p. 8-9

Histology (see Diagnosis)

Histone Deacetylase (HDAC) Inhibitors

  • Dietary fiber essential for butyrate production and HDAC inhibition, July 2017 Newsletter, p. 19-21
  • Broccoli and Brussels sprouts are natural HDAC inhibitors, Article #10, p. 24-25; Article #11, p. 16
  • Potential of HDAC inhibitors in helping to manage fNHL, Article #10, p. 24-25; Article #11, p. 16
  • Sulforaphane as a natural HDAC inhibitor in foods, Article #10, p. 24-25; Article #11, p. 16

Hyperthermia/Heat Therapy/Hot Baths

  • Boosting chemo effectiveness with intraperitoneal hyperthermic chemotherapy, October 2013 Newsletter, p. 14-15
  • Hyperthermia during chemotherapy, Article #8, 8-11; Article #7, p. 25-26

[ return to top ]

________________________________________________________

I

Ibrutinib (Imbruvica)

  • Careful assessment of ibrutinib (imbruvica) recommended for those considering it as a treatment for follicular lymphoma, January 2016 Newsletter, p. 9-10
  • “Ibrutinib IMBRUVICA Side-Effects, Article #6, p. 28-29;  April 2014 Newsletter, p. 3-8; 11-13
  • Results from a Phase 1 trial using Imbruvica with relapsed follicular lymphoma patients, January 2014 Newsletter, p. 13-16
  • Ibrutinib and the BTK gene — off-target reactivity, December 2013 Newsletter, p. 15-18
  • Ibrutinib … a Concern ; Immunity, side effects, clinical trials for follicular lymphoma, BTK gene; September 2013 Newsletter, p. 3-13
  • Ibrutinib’s side effects when used as a genetically-based therapy for treating follicular lymphoma, Article #7, p. 47-50; October 2013 Newsletter, p. 5

Idelalisib (Zydelig)

  • General information plus detailed assessment, Article #6, p. 29-30
  • “Zydelig — Idelalisib — Caution (new concerns published re clinical trials including FDA Alert)”, June 2016 Newsletter, p. 4-6; April 2016 Newsletter, p. 10-12
  • Careful assessment of idelalisib (zydelig) recommended for those considering it as a treatment for follicular lymphoma, January 2016 Newsletter, p. 9-10
  • “Idelalisib (Zydelig) Approved for Relapsed Follicular Lymphoma…BUT”, August 2014 Newsletter, p. 7-9
  • “Idelalisib (Zydelig)… Side-Effects, Effectiveness (New England Journal of Medicine, March 2014)”, April 2014 Newsletter, p. 3-4; 8-13
  • Concerns with Idelalisib (Zydelig) and serious side effects, June 2016 Newsletter, p.4-6; April 2016 Newsletter, p. 10-12, January 2016 Newsletter, p. 9-10; August 2014 Newsletter, p. 7-9; April 2014 Newsletter, p. 3-4 and 8-13; December 2013 Newsletter, p. 15-18; Article #7, p. 47-50
  • Results from a Phase 2 trial using Idelalisib with relapsed indolent lymphoma patients, January 2014 Newsletter, p. 15-16

IgA, August 2021 Newsletter, p. 11-18

Immunity

  • “Follicular Lymphoma — Winning the T Cell Game”  September 2022 Newsletter, p. 3-14
  • The Four Pillar (4PEP) Program and COVID-19, February 2022 Newsletter, p. 2-15
  • “Choose the Best Foods and Supplements for a Stronger Immune System”,  December 2021 Newsletter, p. 10-16
  • Compromised immunity and rapid nodal growth, August 2018 Newsletter, p. 10-11
  • “Seven Surprising Perspectives about the Immune System and fNHL”, June 2013 Newsletter, p. 3-12
  • “Optimizing Immunity for the Winter Season”, January 2013 Newsletter, p. 11-14

Immunoglobulins

  • Research links treatment with rituximab and obinutuzumab to low Ig levels (hypogam),  July 2022 Newsletter, p. 8-12 
  • Immunoglobulin test results and what they mean, Article #5, p. 26-27; February 2015 Newsletter, p. 18-19
  • Recommendation to get Ig levels (IgA, IgG, IgM) tested on a regular basis, January 2012 Newsletter, p. 15-17
  • Low IgA — what it means and what natural strategies may help, March 2020 Newsletter, p. 16-23;  September 2017 Newsletter, p.11-18
  • Why WBC blood tests (lymphocytes & neutrophils) need to be supplemented with immunoglobulin tests, May 2013 Newsletter, p. 11-13
  • Immunoglobulins and maintenance rituximab, Article #7, p. 26-29
  • Immunoglobulins in blood tests, normal range, Article #5, p. 26-27; Article #3, p. 76
  • Immunoglobulins and colostrum, December 2010 Newsletter, p. 18
  • Risks associated with below normal Immunoglobulins, Article #7, p. 28-29

Immunotherapy

  • The gut microbiome and immunotherapy,  February 2023 Newsletter, p. 8-10
  • Where are we with immunotherapy?, April 2023 Mid Month Newsletter, p. 1-8; December 2019 Newsletter, p. 8-11; June 2019 Newsletter, p. 17-22
  • Immunotherapy and the gut microbiome, December 2019 Newsletter, p. 8-11
  • Immunotherapy, October 2016 Newsletter, p. 15

Inflammation and cancer

  • “Follicular Lymphoma — Understanding Inflammation”, August 2022 Newsletter, p. 6-17 
  • FOXP3+ Tregs, a potent prognostic indicator of long-term survival with fNHL, is a master regulator of inflammation, June 2017 Newsletter, p. 10-15
  • Tart cherry juice found to have significant anti-inflammatory effects in human clinical trials, March 2024 Newsletter, p. 3-10
  • Hidden infections and inflammation, October 2018 Newsletter, p. 14-17
  • General information: August 2018 Newsletter, p. 4;  March 2017 Newsletter, p. 9-10; July 2016 Newsletter, p. 15-19

Inner Peace, Article #3, p. 56-57

Insulin levels and cancer, October 2014 Newsletter, p. 13-15; Article #10, p. 22-24

Integrative Medicine

  • “The Winning Battle Plan: Risks with an Alternative Approach”, October 2013 Newsletter, p. 7-9

Iodine, April 2013 Newsletter, p. 24-25

Iron

  • “Cell Growth Supplements that  MUST be Avoided”,  September 2024 Newsletter, p. 10-15
  • Anemia, Iron, and Lymphoma, May 2023 Mid Month Newsletter, p. 1-8; October 2021 Mid Month Newsletter, p. 1-14
  • Need for fNHL patients to avoid iron supplements, August 2018 Newsletter, p. 5-6; April 2017 Newsletter, p. 17-18; January 2015 Newsletter, p. 15; May 2013 Newsletter, p. 16-18; Article #7, p. 14
  • Iron supplements as a possible trigger for transformation, Article #4, p. 14; Article #7, p.14

 

[ return to top ]

_________________________________________

J

[ return to top ]

_________________________________________________

K

Ki-67, Article #5, p. 13; Article #2, p. 31, May 2013 Newsletter, p. 18-19

[ return to top ]

 

________________________________________________

L

Lactoferrin,  May 2023 Mid Month Newsletter, p. 1-8;  June 2023 Newsletter,  p. 2-5

LDH

  • Lactate Dehydrogenase (LDH) blood test reading — what it means for lymphoma survivors, March 2022 Mid Month Newsletter, p. 12-15
  • LDH test, Article #5, p. 23-24
  • LDH and tomato juice, March 2017 Newsletter, p. 15-16
  • Exercise can affect LDH test results, July 2013 Newsletter, p. 23-24
  • Elevated LDH and transformation, Article #4, p.5-6; Article #5, p.23-24; Article #2. p.34

Leonard, Dr. John

  • Expert commentary on 2016 clinical trial results comparing Rituxan and Gazyva, January 2017 Newsletter, p. 20

Lifestyle Strategies (see also Targeted Natural Strategies)

  • “The Time-Tested Plan to PREVENT Follicular Lymphoma Relapse”, July 2024 Newsletter, p. 2-16
  • “Epigenetic Regulators of Follicular Lymphoma: A Reference Guide”, Article #11
  • “Getting Follicular Lymphoma Cells to Die on Their Own”, Article #10
  • “The Four Pillar Epigenetics 4PEP Program”, Article #3
  • All four pillars in the 4PEP program are affected by the gut microbiome, November 2018 Newsletter, p. 10-15
  • Ringleader fNHL genes and enzymes and lifestyle strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-15
  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Updated dietary strategies, Article #3, p. 58-76
  • “Making Changes in Life Following Diagnosis”, May 2013 Newsletter, p. 3-5
  • Epigenetics and lifestyle strategies, Article #3, p. 15-22; Article #11, p. 1-25; Article #10, p. 13-33; Article #2, p. 4-9

Long-Term Survival (also see Planning Horizon)

  • “Extended Survival — Here’s What’s Happening in the Body”,  June 2022 Newsletter, p. 2-5
  • ” 32 Years After Diagnosis: Eradication — Rejuvenation”,  July 2020 Newsletter,  p. 3-9
  • “The Gut Microbiome — Emerging Insight re Cancer Survival”, September 2019 Newsletter, p. 5-13
  • “Does the Choice of Chemo Treatment Really Matter?”; September 2018 Newsletter, p. 8-10
  • Overall Survival Statistics, Article #2, p. 25-29
  • Prognostic Indicators for overall survival, Article #2, p. 29-32
  • Review of research and expert commentary from lymphoma specialists regarding maintenance rituximab and overall survival, March 2016 Newsletter, p. 4-16
  • No overall survival advantage found between watchful waiting, chemoimmunotherapy, and initial treatment with rituximab monotherapy,  February 2016 Newsletter, p. 4-6
  • “Follicular Lymphoma Survival: A Gold Star to Stanford and the Spanish”, May 2018 Newsletter, p. 8-14
  • “Follicular Lymphoma Survival: Latest Treatment and Survival Statistics from the USA”, May 2018 Newsletter, p. 5-8
  • Event-Free Survival (EFS) as a prognostic indicator, January 2015 Newsletter, p. 11-14
  • “Advancements in Research toward Achieving 30 Years of Healthy Survival with Follicular Lymphoma”,  October 2017 Newsletter,  p. 2-10
  • “Our Four Groups of Members: Who They Are and What They Need”, September 2011 Newsletter, p. 3-17
  • “Observations and Lessons Learned During a 30 Year Journey with Follicular Lymphoma” (an account by Robert G. Miller), July 2018 Newsletter (entire)
  • “Grateful for 25 Years Since Diagnosis: The Key Strategic Factors”, July 2013 Newsletter, p. 2-7
  • “The “How to” Details for Lengthening Your Life — Getting into the Thrive Zone with Epigenetics”, May 2011 Newsletter, p. 2-24
  • “From Knowledge to Success… 9 Essential Steps in Managing fNHL”, March 2011 Newsletter, p. 3-9
  • “The Five Key Things That Got Me This Far”, January 2011 Newsletter, p. 3-9
  • “Cracking the Code for Entering the Thrive Zone”, December 2010 Newsletter, p. 4-6
  • “Strategic Requirements for the Thrive Zone”, December 2010 Newsletter, p. 6-8
  • “The Seven Premises in Understanding and Managing fNHL”, November 2010 Newsletter, p. 3-12
  • Planning for transformation: Most important considerations, Article #6, p.13-14; January 2009 Newsletter, p. 3-4
  • ” 40 Must Know Things Learned After 22 Years — Especially Important for the Newly Diagnosed”, July 2010 Newsletter, p. 4-10
  • ” Maintaining a Clinical Remission”, September 2010 Newsletter, p. 6-9
  • New data on overall survival for fNHL patients diagnosed before the age of 40, November 2015 Newsletter, p. 15-17
  • Stanford research on overall survival (OS), Article #2, p. 26-29

Lymph Fluid

  • How to purify the lymph fluid, Article #7, p. 37-38; December 2015 Newsletter, p.24-25; May 2016 Newsletter, p. 15-20; Article #3, p.36-37
  • The fascinating lymphatic system, Article #2, p. 10-12

Lymphocytes

  • Absolute lymphocyte count (ALC) in blood tests — what it means for lymphoma survivors, October 2022 Newsletter, p. 15-18; February 2022 Mid Month Newsletter, p. 1-9
  • Low lymphocyte counts in blood tests, Article #5, p.21;  October 2014 Newsletter, p. 5-12

[ return to top ]

________________________________________________

M

m7- FLIPI

  • m7-FLIPI as a potentially new and better forecasting tool, Article #5, p. 14-15;  September 2015 Newsletter, p. 4-6; 10-14: Article #2, p.33

Magnesium

  • Update on magnesium supplements,  June 2022 Newsletter, p. 15-17
  • General information: June 2020 Newsletter, p. 11; December 2019 Newsletter, p. 2-3; January 2019 Newsletter, p. 4;  December 2016 Newsletter, p. 19-20

Maintenance Rituximab

  • “Learning How Maintenance Rituximab Relates to Overall Survival” (update to November 2021), November 2021 Mid Month Newsletter, p. 1-11
  • Proven negative effect of maintenance rituximab,  October 2024 Newsletter,  p. 14-19
  • Data published in March 2022 links treatment with rituximab or obinutuzumab to low Ig levels (hypogam), July 2022 Newsletter, p. 8-12
  • “Rituximab: Two Recent Published Warnings”, July 2017 Newsletter, p. 10-13
  • Maintenance Rituximab — brief 2019 update, March 2019 Newsletter, p.6-10
  • “Maintenance Rituximab — for How Much Longer?”, March 2016 Newsletter, p. 4-16
  • Member feedback re pros and cons of Maintenance Rituximab, May 2017 Newsletter, p. 16-17
  • “Maintenance Rituximab Now Considered Optional by Experts”, September 2016 Newsletter, p. 12-15
  • “The Impact of Rituximab on Long-Term Immunity”, September 2016 Newsletter, p. 15-17
  • General information, Article #6, p. 17-19
  • “End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma”, November 2014 Newsletter, p. 5-6
  • “Strategies to Stay Healthy While on Maintenance Rituximab”, March 2015 Newsletter, p. 16
  • Study published in October 2014 shows failure of Maintenance Rituximab (MR) to produce significantly beneficial outcomes in patients receiving MR as compared to those patients receiving rituximab only in the event of relapse, October 2014 Newsletter, p. 15-17
  • “Maintenance Rituximab Update, Pros, Cons, Strategies”, January 2014 Newsletter, p. 17-18
  • “More Cautions re Maintenance Rituximab”, June 2014 Newsletter, p. 15-17
  • Testing immunoglobulin (Ig) levels advised before and after treatment with maintenance rituximab, December 2014 Newsletter, p. 9-11
  • General information, Article #7, p. 26-29
  • Study shows low tumor burden fNHL patients on watch and wait do just as well in first four years as low tumor burden patients treated with MR, October 2012 Newsletter, p. 11

Master Strategy

  • The master strategy for follicular lymphoma regression, October 2019 Newsletter, p. 17-19; December 2015 Newsletter, p. 28-29, Article #3,  p.44 (also see our video under “Videos” tab) 

Melatonin

  • Generating natural melatonin with sunlight, Article #3, p. 51-52; March 2014 Newsletter, p. 20

Metabolic Disease

  • The “Warburg Effect” — Why it is important for spontaneous regression of follicular lymphoma, Article #10, p. 6-7; 22-24

Metformin, July 2016 Newsletter, p. 19-20

Methylation

  • DNA Methylation and natural regression of follicular lymphoma, August 2015 Newsletter, p. 2-15; May 2014 Newsletter, p. 8-10

Microbiome

  • “Gut Bacteria Akkermansia Promotes Lymphoma Survival”, October 2023 Newsletter, p. 3-11
  • “New Knowledge re the Gut Microbiome with Application to Lymphoma”, February 2023 Newsletter, p. 4-18
  • “2022 research on T Cells and the gut microbiome,  September 2022 Newsletter, p. 11-13
  • 2022 update on glyphosate in foods, with emphasis on its impact on the gut microbiome, March 2022 Newsletter, p. 2-9
  • “Four Stages Toward Achieving a Healthy Gut”, October 2021 Newsletter, p. 2-14
  • “The Liver, Bile, Bile Acids, Gut Bacteria and Lymphoma”, July 2021 Newsletter, p. 3-12
  • Key “need to know” facts about the gut microbiome, diet and follicular lymphoma, Article #3, p. 63-64
  • “Phytochemicals for a Healthier Microbiome”, July 2020 Newsletter, p. 10-15
  • The gut microbiome and COVID-19, January 2021 Mid Month Newsletter, p. 1-13
  • “Unsuspected Toxins Harm the Gut Microbiome”,  March 2021 Newsletter, p. 12-20
  • The “new era” in cancer management and the gut microbiome, January 2021 Newsletter, p. 10-14
  • Our gut microbiota are an important “third population” of cells, January 2020 Newsletter, p. 2-4
  • Dietary concerns with the gut microbiome during  chemo, and recovery from chemo Article #8, p. 17-18
  • The importance of the microbiome or gut microbiome for lymphoma survivors is also discussed in the following newsletters: October 2020 Newsletter, p. 9-13; September 2019 Newsletter, p. 5-13; July 2019 Newsletter, p. 10-13; April 2019 Newsletter, p. 5-9; February 2019 Newsletter, p. 17; November 2018 Newsletter, p. 10-15; October 2018 Newsletter, p. 5-7; February 2018 Newsletter, p. 18-21November 2017 Newsletter, p. 17-18June 2017 Newsletter, p. 12-15, October 2016 Newsletter, p. 4-15; April 2017 Newsletter, p. 7-12; January 2017 Newsletter, p. 15-16; January 2016 Newsletter, p. 11-16; June 2014 Newsletter, p. 17-20; November 2013 Newsletter, p. 6-9, Article #3, p. 53-54

Microenvironment

  • Data from cancer survivors shows greater diversity of bacteria in the tumor microbiome is linked to higher overall survival., September 2019 Newsletter, p. 5-13
  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Immune nodal microenvironment and long-term survival, January 2015 Newsletter, p. 5-10; Article #11, p. 20-25; Article #10, p. 7; Article #2, p. 36-37;  December 2014 Newsletter, p. 16-17
  • Original, symbolic portrayal of “corralling” lymphoma in nodal microenvironment, December 2009 Newsletter, p. 3-11
  • Epigenetics and nodal microenvironment, Article #10, p. 7

Milk Thistle

  • Epigenetic anti-cancer effects of milk thistle (silibinin), Article #11, p.11
  • Bowel inflammation and milk thistle, October 2016 Newsletter, p. 11-12

MIME, Article #6, p.27

Mitochondria

  • Urolithin A associated with activation of mitochondria,  January 2024 Newsletter, p. 3-20
  • Vitamin B complex and mitochondria, April 2022 Mid Month Newsletter, p. 8-11
  • Warburg effect (cancer as a metabolic disorder), Article #10, p. 6-7;  May 2016 Newsletter, p. 15-20
  • Pomegranates, red berries, and mitochondria, April 2019 Newsletter, p. 13-15
  • Resveratrol and mitochondria, Article #10, p.24
  • Exercise and mitochondrial stimulation, July 2013 Newsletter, p. 10-11

MRI

  • Using MRI scans for fNHL, Article #5, p. 32-33; September 2013 Newsletter, p. 18-21

mTOR

  • The mTOR gene, alcohol, and lymphoma, November 2013 Newsletter, p. 9-11
  • Quercetin and the mTOR gene, November 2013 Newsletter, p. 13-15

Mushrooms , November 2021 Newsletter, p. 12-20

Myc Gene

  • Connection found between epigenetic changes in cancer cells and the Myc gene, Article #10, p. 26-27; Article #11, p. 10-11; 17; 20-25; December 2012 Newsletter, p. 10-13
  • Testing for Myc gene expression, Article #5, p. 36; Article #4, p.22
  • Vitamin D found to inhibit production and function of protein cMyc, Article #10, p.13-16; February 2013 Newsletter, p. 6-8

[ return to top ]

N

NAD, January 2024 Newsletter, p. 8

Nanoplastics

  • The adverse health impacts of nanoplastics and implications for lymphoma survivors,  September 2024 Newsletter. p. 3-9

Natural (Spontaneous) Regression 

  • “Natural Regression: Update on an Achievable Miracle”, October 2020 Newsletter, p. 4-15
  • Natural regression: A personal example (Robert), Article #3, p. 10-11
  • “Healthy Microbiome Leads to Natural Regression”; February 2018 Newsletter, p. 18-21
  • Dr. Saul Rosenberg’s research on “watch and wait” and how it helps us understand spontaneous (natural) regression, February 2014 Newsletter, p. 5-9
  • Epigenetics, follicular lymphoma, and natural regression, Article #11, p. 21-22
  • “Updating What We Know About Spontaneous (Natural) Regression”, February 2014 Newsletter, p. 8-11
  • “Must know” details about SR for follicular patients, Article #10, p. 1-10; May 2018 Newsletter, p. 17-19
  • Frequent hiking in the sun and spontaneous regression, Article #10, p. 8-10; July 2013 Newsletter, p. 7-15
  • “A Real Life Example of an Epigenetic Intervention Leading to Spontaneous Regression”, Article #10, p. 8-10

Nicotinamide (Niacin or B3)

  • May 2024 Newsletter, p. 15-17;  November 2023 Newsletter, p. 2-14

NK Cells

  • Natural strategies to increase NK cell count and improve immunity,  March 2024 Newsletter, p.14-18; June 2023 Newsletter, p. 5-8
  • Results of a pilot clinical trial with follicular lymphoma survivors with CAR-NK, November 2023 Newsletter, p. 2-14

Nuts, September 2017 Newsletter, p.19-21

Nutrition

  • Essential elements in a healthy balanced diet, June 2024 Newsletter, p. 3-6; May 2023 Newsletter, p. 1-16
  • Latest research on the gut microbiome applied to the 4PEP program Nutrition Pillar,  February 2023 Newsletter, p. 15-18
  • The nutrition pillar and T Cells,  September 2022 Newsletter, p. 9-10
  • Latest dietary and supplement suggestions, Article #3, p. 57-83
  • “Star Performers of the Nutritional Pillar”, November 2020 Newsletter, p. 2-15
  • “Secrets for Optimizing the Nutritional Pillar”, mid-November 2020 Newsletter, p. 2-10
  • “Nutrition Illumination”, January 2019 Newsletter, p. 5-18
  • Reference list of key nutrients linked to their food sources, January 2020 Newsletter, p. 15-17
  • “Diet and Supplements: Key Considerations for Follicular Lymphoma Survivors”, June 2018 Newsletter, p. 8-21
  • “Applying Nutrition Properly: The Two Population Fact”, April 2016 Newsletter, p. 4-8

[ return to top ]

________________________________________________________

O

Olive Oil, April 2019 Newsletter, p. 3

Omega 3 Fatty Acids

  • Update on Omega 3 supplements, June 2022 Newsletter, p. 9-12
  • “Omega 3s: Update on a Vital Nutritional Factor”, September 2021 Newsletter, p. 2-17
  • Clear out the chemo debris to optimize the eradication phase (fish oil and resolvins), October 2021 Newsletter, p. 14-18

Omega 6:3 ratio, Article #11, p. 11

Oncogenes, August 2015 Newsletter, p. 8-11

Organic Foods,  September 2019 Newsletter, p. 18-19; March 2019 Newsletter, p. 14-22; November 2018 Newsletter, p. 15-21; August 2014 Newsletter, p. 21-23

Organochlorines

  • As a risk factor for lymphoma, Article #11, p.6-7; Article #3, p. 76
  • Risk factors associated with chlorinated water, May 2017 Newsletter, p. 10-12;  Article #3, p. 62-63

[ return to top ]

__________________________________________________________

P

PACE, Article #6, p.27

POD24, April 2022 Newsletter, p.11

Paradigm Shift (in understanding and treating fNHL), August 2015 Newsletter (entire); October 2014 Newsletter, p. 4-5; Article #10, p. 3-4; Article #2, p. 4-6; March 2014 Newsletter, p. 10-11

Paraneoplastic Syndrome, Article #3, p.76

PCR, May 2019 Newsletter, p. 11-12

Pesticides (see Herbicides and Pesticides)

PET scans

  • Research on high frequency of false positive PET scans in regard to diagnosis of relapsed lymphoma, Article #5, p. 30-31
  • Risks of over-exposure to radiation, Article #5, p. 30-34; Article #10, p. 23; May 2015 Newsletter, p. 12-16;

PI3K/Akt Signaling Pathway

  • Urolithin A derived from dietary items can influence the PI3K/Akt pathway, April 2019 Newletter, p. 15
  • Quercetin as a dual-specific activator of mTOR and the PI3K/Akt signaling pathway, November 2013 Newsletter, p. 13-15

Planning Horizon (also see Long-Term Survival)

  • ” 32 Years After Diagnosis: Eradication — Rejuvenation”,  July 2020 Newsletter,  p. 3-9
  • “Advancements in Research toward Achieving 30 Years of Healthy Survival with Follicular Lymphoma”,  October 2017 Newsletter,  p. 2-10
  • “Our Four Groups of Members: Who They Are and What They Need”, September 2011 Newsletter, p. 3-17
  • “Grateful for 25 Years Since Diagnosis: The Key Strategic Factors”, July 2013 Newsletter, p.2-7
  • “From Knowledge to Success … 9 Essential Steps in Managing fNHL”, March 2011 Newsletter, p. 3-9
  • “The Five Key Things That Got Me This Far”, January 2011 Newsletter, p. 3-9
  • “Cracking the Code for Entering the Thrive Zone”, December 2010 Newsletter, p. 4-6
  • “Strategic Requirements for the Thrive Zone”, December 2010 Newsletter, p. 6-8
  • Factors to consider in planning for 20 ++ years of survival, February 2010 Newsletter, p. 2-6
  • Planning for transformation: Most important considerations, Article #6, p.16; January 2009 Newsletter, p. 3-4
  • An overall strategy for managing fNHL for long-term success, February 2009 Newsletter, p. 2-6
  • “40 Must Know Things Learned After 22 Years — Especially Important for the Newly Diagnosed”, July 2010 Newsletter, p. 4-10
  • ” Maintaining a Clinical Remission”, September 2010 Newsletter, p. 6-9

Plastics

  • The adverse health impacts of nanoplastics and implications for lymphoma survivors,  September 2024 Newsletter. p. 3-9
  • “Microplastics and Their Association with Lymphoma”, May 2022 Newsletter, p. 11-17
  • Chemicals in plastic and their toxic impact on follicular lymphoma, March 2022 Newsletter, p. 10-16
  • Microplastics found in bottled water, April 2018 Newsletter, p. 8-13
  • Dangers of plastic ingestion in food and beverages, May 2017 Newsletter, p. 12-14

Pomegranates, January 2024 Newsletter, p. 4 and p. 9; April 2019 Newsletter, p.12-16

Prebiotics, March 2017 Newsletter, p. 11-13

Prevention

  • Lifestyle strategies and cancer prevention, Article #2, p. 4-6; November 2016 Newsletter, p. 6-10;  February 2014 Newsletter, p. 11-13

Probiotics, October 2016 Newsletter, p. 9Article #11, p. 12

Problematic Nodes, Article #6, p. 6-7

Progression-Free Survival,  August 2019 Newsletter, p. 12-13; May 2016 Newsletter, p. 9-12

Protein (in food),  August 2024 Newsletter, p. 13-17; May 2022 Mid Month Newsletter, p. 1-11

Protein Powder Supplements

  • “Cell Growth Supplements that  MUST be Avoided”,  September 2024 Newsletter, p. 10-15
  • Protein powder supplements are foods to avoid for cancer patients, May 2022 Mid Month Newsletter, p. 9-11; Article #10, p. 26-27; Article #11, p. 9-10; Article #7, p. 43-44; August 2018 Newsletter, p.5; December 2012 Newsletter, p. 12-13; Article #3, p. 14 & 67-68
  • Protein powders, glutamine, and transformation, Article #4, p.14
  • Avoidance advised concerning whey protein, Article #10, p. 26-27; Article #3, p. 14 & 67-68; June 2012 Newsletter, p. 17-19

Psychological Factors and treatment options, Article #1

[ return to top ]

________________________________________________________

Q

Quercetin

  • Epigenetic anti-cancer effects of quercetin, Article #11, p. 13; November 2013 Newsletter, p. 13-15
  • Quercetin in apples “natural mimic” of many enzyme-based cancer therapies now under development, November 2013 Newsletter, p. 13-15

[ return to top ]

_____________________________________________________________

R

R-Bendamustine (see Bendamustine)

R-CHOP

  • SUV values may indicate when CHOP or R-CHOP is the preferred treatment choice, July 2021 Newsletter, p. 13-19
  • Effectiveness of Bendamustine vs. CHOP compared in Phase III trial, July 2017 Newsletter, p. 14-16
  • Importance of reserving use of R-CHOP for transformation, Article #4, p. 8-9; Article #6, p. 13-14
  • Genetic test developed based on m7 research that helps to predict treatment effectiveness, February 2020 Newsletter, p.17-19
  • Comparison of R-CHOP and R-Bendamustine when used as an initial treatment, Article #7, p. 24-25
  • Gene MLH1 status can block response to CHOP, April 2015 Newsletter, p. 7-9
  • General information, Article #4, p. 1-9; Article #6, p. 13-14; Article #7, p.11-12
  • As treatment for transformation, Article #4, p. 8-9
  • CHOP and the heart, July 2016 Newsletter, p. 19-20
  • Beet root juice and metformin during R-CHOP treatment, July 2016 Newsletter, p. 19-20
  • R-CHOP as a choice for initial therapy, Article #7, p. 19-20; Article #6, p.13-14
  • The importance of  Co-Enzyme Q-10 when receiving CHOP, Article #8, p.14
  • Follicular lymphoma survivors with a mutated EZH2 gene at diagnosis — implications for taking R-CHOP vs. R-Bendamustine, October 2022 Mid Month Newsletter, p. 2-6

R-CP, Article #6, p.27

R-CVP, Article #6, p.19

R-EPOCH, Article #6, p. 13

R-ESHAP, Article #6, p. 27

R-GDP

  • Article #6, p. 13; 25-26;  Article #4, p.9-10
  • “The Merits of R-GDP (New Research plus Personal Experience)”, November 2014 Newsletter, p. 21-22

R-GCVP, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9

R-Lipoic Acid,  June 2022 Newsletter, p. 8-9

R-ICE, Article #6, p. 13 & 26

R-PCR (PCR), Article #6, p.27

Radiation

  • “Low Dose Radiation Update with a Detailed Personal Account”, December 2013 Newsletter, p. 5-7
  • General discussion of research pertaining to the use of low dose field radiation therapy (LDIFRT) in treating fNHL, Article #6, p. 14-15
  • Lymphoma in the eye region and radiation treatments, September 2014 Newsletter, p. 11-12
  • “Caution re Eight or More CT Scans Plus PET”, Article #5, p. 33-34;  May 2015 Newsletter, p. 12-16
  • Tocotrienols and their potential for mediating radiation damage, Article #5, p. 34; July 2013 Newsletter, p. 19-22.
  • Radiation for treatment of nodes of cosmetic concern, Article #7, p. 35-36

Rainbow Salad, Article #3, p. 73

Raspberries, January 2024 Newsletter, p. 10; April 2019 Newsletter, p. 12-16

Red Palm Oil

  • Epigenetic anti-cancer effects of tocotrienols in red palm oil, Article #11, p. 17, February 2016 Newsletter, p. 21; July 2013 Newsletter, p. 19-22; February 2013 Newsletter, p. 9-10
  • Red Palm Oil recipe, January 2020 Newsletter, p. 5-6
  • Red palm oil may help to counteract negative effects of radiation, Article #5, p. 34; May 2015 Newsletter, p. 14-16
  • Instructions for mixing and consuming red palm oil, June 2016 Newsletter, p. 17-18
  • Red palm oil and gene p53, June 2015 Newsletter, p. 21-22

Relapse

  • Understanding follicular lymphoma relapse, July 2024 Newsletter, p. 3-5
  • Preventing relapse with the 4PEP Program,  July 2024 Newsletter, p. 6-15
  • ” Relapse Warning Signs — What to Do”,  July 2023 Newsletter, p. 3-19
  • “Is Relapse Inevitable?”,  June 2023 Mid Month Newsletter, p. 1-9
  • “Follicular Lymphoma Relapse — Things to Know, What to Do” April 2022 Newsletter, p. 2-21
  • “Let’s Take On the Challenge of Relapse”, October 2019 Newsletter, p. 6-9
  • “Finished Treatment? Now What?”, March 2019 Newsletter, p.5-13
  • How to prevent or delay relapse after first treatment, October 2015 Newsletter, p. 19-23
  • “The Critical Window of Opportunity in Managing Follicular Lymphoma. Don’t Miss It”,  February 2017 Newsletter, p. 9-11
  • Treatment options in the event of relapse after treatment with R-Benda, October 2015 Newsletter, p. 13-19
  • Guidelines for when to treat relapse situations, Article #6, p. 8-9; August 2013 Newsletter, p. 19-21

Reno, Jamie, review of book, “Hope begins in the dark: Fifty lymphoma survivors tell their exclusive life stories”, February 2008 Newsletter, p. 15

Resolvins,  October 2021 Newsletter, p. 14-16

Resveratrol

  • Epigenetic anti-cancer effects of resveratrol, Article #11, p. 13-14
  • Reduced dosage suggested for daily supplementation with trans-resveratrol, May 2012 Newsletter, p. 15-16
  • Research on resveratrol and transformed fNHL cells, Article #4, p. 24; June 2012 Newsletter, p. 14-16

Retinoids

  • Retinoids and vitamin D,  June 2024 Newsletter, p. 16-17
  • Potent anticancer properties discovered in retinoic acid, October 2018 Newsletter, p. 17-18
  • Retinoids crucial for the proliferation of FOXP3+ Treg cells which are crucial for long-term survival with fNHL, June 2017 Newsletter, p. 6-9, 12-15
  • Best food sources for vitamin A,  June 2017 Newsletter, p. 6-9: February 2016 Newsletter, p. 14-22
  • Desiccated liver supplement a good source of retinoids, March 2019 Newsletter, p. 3
  • Epigenetic anticancer effects of retinoids; Article #11, p. 14
  • Cod liver oil as a daily supplement, Article #3, p. 67
  • Retinoids and bowel health, October 2016 Newsletter, p. 12
  • Liver smoothie recipies, July 2017 Newsletter, p. 23-24
  • Assuring adequate amounts of retinoids in the diet is tricky, October 2016 Newsletter, p. 16-20

Revlimid (Lenalinomide)  

  • Trial results from 2023 comparing Bendamustine to Revilimid for a first treatment, April 2024 Newsletter, p. 8-9
  • Results of the RELEVANCE trial, May 2019 Newsletter, p. 10-11
  • “Lenalinomide/Revlimid Confusion”, September 2018 Newsletter, p. 11-13
  • General information, Article #6, p. 27

Rituximab (also see Maintenance Rituximab)

  • “Learning How Maintenance Rituximab Relates to Overall Survival” (update to November 2021), November 2021 Mid Month Newsletter, p. 1-11
  • Proven negative effect of maintenance rituximab,  October 2024 Newsletter,  p. 14-19
  • Data published in March 2022 links treatment with rituximab or obinutuzumab to low Ig levels (hypogam), July 2022 Newsletter, p. 8-12
  • New rituximab biosimilars, September 2019 Newsletter, p. 18-19
  • “Rituximab: Two Recent Published Warnings”, July 2017 Newsletter, p. 10-13
  • Rituximab as stand alone initial treatment, Article #6, p. 16-17
  • “Maintenance Rituximab — for How Much Longer?,  March 2016 Newsletter, p. 4-16
  • Member feedback re pros and cons of Maintenance Rituximab, May 2017 Newsletter, p. 16-17
  • “Maintenance Rituximab Now Considered Optional by Experts”, September 2016 Newsletter, p. 12-15
  • “The Impact of Rituximab on Long-Term Immunity”, September 2016 Newsletter, p. 15-17
  • “End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma”, November 2014 Newsletter, p. 5-6
  • No overall survival advantage found between watchful waiting, chemoimmunotherapy, and initial treatment with rituximab monotherapy,  February 2016 Newsletter, p. 4-6
  • Gene CDKN2A status predicts overall survival time for patients treated with rituximab, April 2015 Newsletter, p. 5-7
  • “Strategies to Stay Healthy While on Maintenance Rituximab”, March 2015 Newsletter, p. 16
  • Research study finds prolonged use of rituximab heightens risk of suppressed long-term immunity, October 2011 Newsletter, p. 9-12

Rosenberg, Dr. Saul

  • Dr. Rosenberg’s research and its implications for explaining spontaneous regression, February 2014 Newsletter, p. 2; 5-9
  • Dr. Rosenberg’s research on watch and wait, Article #5, p. 12-14; March 2008 Newsletter, p. 3-6; Article #2, 26-29

Roundup (Glyphosate)

  • Even low doses of glyphosate in foods can be toxic, September 2023 Newsletter, p. 7-13
  • 2022 update on glyphosate in foods, with emphasis on its impact on the gut microbiome, March 2022 Newsletter, p. 2-9
  • “Glyphosate: Lifesaving New Data”, August 2021 Newsletter, p. 3-10
  • “Glyphosate/Roundup — New Concerns with Food”, July 2019 Newsletter, p. 7-15
  • “Relentless Concerns with Roundup”, August 2018 Newsletter, p. 17-18
  • Roundup and toxic exposure risks, May 2017 Newsletter, p. 5-7
  • Roundup weedkiller classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19

[ return to top ]

________________________________________________________

S

SAD (Seasonal Affective Disorder) , December 2015 Newsletter, p. 21-22 

SUV values,  April 2022 Newsletter, p. 12-13

Scans

  • “Scanning Savvy (update to January 2023), January 2023 Newsletter, p. 2-14
  • “Is CT Scanning Beneficial after First Therapy for FL?”,  July 2022 Newsletter, p. 12-15
  • “Scanning: Facts to Know for 2021”, July 2021 Mid Month Newsletter, p. 2-11
  • SUV values may indicate when CHOP or R-CHOP is the preferred treatment choice, July 2021 Newsletter, p. 13-19
  • “Update: Radiation Risk from Scans — With Suggestions”,  October 2020 Newsletter, p. 16-21
  • Vitamin E tocotrienols found to reduce damage from radiation scanning, Article #5, p. 34; July 2013 Newsletter, p. 19-22
  • PET scans and false positive results, Article #5, p. 30-31
  • Radiation dangers, Article #5, p. 33-34; May 2015 Newsletter, p. 12-16
  • “Caution re Eight or More CT Scans Plus PET”, May 2015 Newsletter, p. 12-16 (see correction to 4 or more scans in June 2015 Newsletter, p.17-19, Article #5, p. 33-34)
  • Treatment decisions and scans, Article #7, p. 9-10
  • Using MRIs and ultrasounds for routine scanning, Article #5, p. 32-33
  • Combined PET and CT scanning, May 2015 Newsletter, p. 12-16; Article #5, p. 30-31
  • Recommendations for CT scan frequency, Article #5, p. 33-34; December 2013 Newsletter, p. 19-22
  • Secondary Cancers, May 2009 Newsletter, p. 12
  • Effectiveness of interim scannning during first-line treatment, October 2022 Mid Month Newsletter, p. 7-8

Selenium

  • Epigenetic anti-cancer effects of selenium, Article #11, p. 14-15
  • Gene P53 and selenium, February 2013 Newsletter, p. 9-10

Shiitake Mushrooms,  October 2019 Newsletter, p.5-6

Sinus Congestion

  • Using coconut oil for sinus congestion,  Article #3,  p.76

Sleep

  • Tart Cherry Juice found to help promote better sleep,  March 2024 Newsletter, p. 7-8
  • “Sleep Expert Provides Latest Data on Three Common ‘Sleep Disruptors’ — Cannabis, Alcohol and Caffeine”, October 2022 Newsletter, p. 2-12
  • The Sleep Pillar and T Cells,  September 2022 Newsletter,  p. 9-10
  • “The Pandemic and the Sleep Pillar”,  May 2021 Mid Month Newsletter, p. 1-11
  • “Understanding How Sleep Can Extend Survival Time”, January 2020 Newsletter, p. 9-12
  • “Peaceful Slumber at 3 AM”,  June 2020 Newsletter, p. 7-10
  • Epigenetic anti-cancer effects of quality sleep, Article #10, p. 19-21; Article #11, p. 14-15
  • Importance of quality sleep, August 2018 Newsletter, p. 8; March 2018 Newsletter,  p. 17; May 2017 Newsletter, p. 20-21; December 2015 Newsletter, p. 26-27; August 2015 Newsletter, p. 19-21; June 2015 Newsletter, p. 11-13: January 2013 Newsletter, p. 16-17; Article #3, p. 40-41
  • “Sleep Deprivation Alters Genetic Expression …. Latest Research”, March 2013 Newsletter, p. 8
  • Circadian clock linked to tumor suppression genes in mice, January 2018 Newsletter, p. 15-16
  • Bedtime snack doubles as a sleeping pill, December 2016 Newsletter, p. 19-20
  • Importance of totally dark room and sleep mask, Article #3, p. 52
  • Dietary fiber may help with sleep problems, March 2017 Newsletter, p. 11-13
  • Poor sleep linked to dietary fat and sugar, February 2016 Newsletter, p. 21-22
  • Quality sleep and chronic stress, Article #10, p. 19-20
  • Natural technique for reinforcing the “hormone twins” (Vitamin D and melatonin) for a better night’s sleep, Article #3, p. 51-52
  • The importance of sleep during chemotherapy treatments, Article #8, p. 19-20

Spontaneous (Natural) Regression (SR)

  • “Natural Regression: Update on an Achievable Miracle”, October 2020 Newsletter, p. 4-15
  • Natural regression: A personal example (Robert), Article #3, p. 10-11
  • “Healthy Microbiome Leads to Natural Regression”; February 2018 Newsletter, p. 18-21
  • Dr. Saul Rosenberg’s research on “watch and wait” and how it helps us understand spontaneous (natural) regression, February 2014 Newsletter, p. 5-9
  • Epigenetics, follicular lymphoma, and natural regression, Article #11, p. 21-22
  • “Updating What We Know About Spontaneous (Natural) Regression”, February 2014 Newsletter, p. 8-11
  • “Must know” details about SR for follicular patients, Article #10, p. 1-10; May 2018 Newsletter, p. 17-19
  • Frequent hiking in the sun and spontaneous regression, Article #10, p. 8-10; July 2013 Newsletter, p. 7-15
  • “A Real Life Example of an Epigenetic Intervention Leading to Spontaneous Regression”, Article #10, p. 8-10

Stages of Follicular Lymphoma, Article #5, p. 7-8; Article #2, p.16; Article #7, p. 7-8

Stem Cells

  • Blood stem cells and Urolithin A,  January 2024 Newsletter, p. 3-10
  • Stem cells and the “eating window”, October 2018 Newsletter, p. 10-13
  • Stem cells and anti-aging, January 2018 Newsletter, p. 6-7
  • Stem cells and vitamin C, November 2017 Newsletter, p. 9-12

Stem Cell Transplants (SCTs)

  • SCT research results (August 2013), September 2013 Newsletter, p. 13-17
  • SCTs and transformation, Article #4, p. 12; 20-22
  • Comparative data on relative effectiveness of chemotherapy, auto SCTs and allo SCTs in treating transformation in fNHL patients, April 2013, p. 17-20
  • Research on rituximab resistance and SCT outcomes, June 2014 Newsletter, p. 15-17
  • General information, Article #6, p. 22-25; Article #7, p. 29-31; August 2012 Newsletter, p. 17-18
  • Research on stem cell transplants and fNHL, including overall survival findings and key information on genetic factors, March 2013 Newsletter, p. 8-13

Stress

  • The Sleep/Stress Pillar and T Cells,  September 2022 Newsletter,  p. 9-10
  • “Chronic Stress and Lymphoma Progression”,  May 2022 Newsletter, p. 2-10
  • “Anxiety Linked to Tumor Growth: Suggestions with Insight”, July 2017 Newsletter, p. 4-12
  • “How Stress is Associated with Follicular Lymphoma”, December 2014 Newsletter, p. 17-23
  • Potentially harmful epigenetic effects of stress for cancer patients, Article #10, p. 21-22; Article #11, p. 15-16; October 2016 Newsletter, p. 22
  • Stress and serotonin, June 2019 Newsletter, p. 15-17
  • Stress, magnesium and vitamin B6, December 2019 Newsletter, p. 2-3
  • Stress and loneliness, December 2018 Newsletter, p. 15-17
  • Cortisol, stress and cancer, Article #10, p. 21-22; Article #11, p. 15-16
  • Dietary fiber may help with stress problems, March 2017 Newsletter, p. 11-13
  • Chronic mental stress, Article #3, p. 53-55

Sulforaphane

  • Epigenetic anticancer effects of sulforaphane, Article #10, p. 24-25; Article #11, p. 16
  • Sulforaphane in broccoli, broccoli sprouts, and Brussels sprouts, a natural histone deacetylase (HDAC) inhibitor, February 2013 Newsletter, p. 5-6; April 2015 Newsletter, p.16-17

Sugar

  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • Dietary challenges in reducing sugar in the diet, October 2014 Newsletter, p. 13-15; January 2013 Newsletter, p. 5-9
  • Sugar as risk factor for cancer, Article #10, p. 22-24; Article #11, p. 10-11; Article # 3, p. 39-40 and 63-65; November 2017 Newsletter, p. 7-8
  • Exercise as a strategy for reducing negative impact of sugar, Article #7, p. 36-37; Article #3, p. 39-40

Sunlight

  • “More Good News re Sunshine”,  March 2024 Newsletter, p. 11-14
  • “Sunshine Has No Equal Update to April 2023”,  April 2023 Newsletter, p. 9-20
  • Sunshine and T Cells,  September 2022 Newsletter, p. 5-6
  • “SARs Meets Sunshine”, June 2021 Mid Month Newsletter, p. 1-7
  • “Sunshine Has No Equal”, September 2020 Newsletter, p. 9-21
  • “Five Lesser Known Benefits of Sunshine”, June 2019 Newsletter, p. 6-12
  • Sunlight exposure enhances good gut bacteria, December 2019 Newsletter, p. 16-19
  • New cautions re sunscreens, June 2019 Newsletter, p. 12-14
  • Sunlight activates FOXP3+ Treg cells crucial to long-term survival with fNHL, June 2017 Newsletter, p. 3-6; 10-12
  • Sunlight may be the most potent source of vitamin D, Article #10, p.14-16; Article #11, p. 18; Article #3, p. 29-34
  • New research reveals natural blue light in sunlight mobilizes anticancer activity in T cells, February 2017 Newsletter, p. 14-16
  • Optimizing the “light diet”, August 2018 Newsletter, p. 12-17
  • Residing in latitudes north of 55 degrees N associated with shorter overall survival time for lymphoma survivors, Article #10, p.15; November 2013 Newsletter, p. 15-16
  • MIT scientist proposes dietary sulphur intake and sunlight exposure are essential keys to optimal health, November 2011 Newsletter, p. 19-20
  • Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, Article 10, p. 15; March 2013 Newsletter, p. 17-18

Supplement Use

  • “Cell Growth Supplements that  MUST be Avoided”,  September 2024 Newsletter, p. 10-15
  • “An Updated Review of Select Supplements to Combat Follicular Lymphoma”,  June 2022 Newsletter, p. 6-21
  • List of suggested supplements, Article #3, p. 78-82
  • “Diet and Supplements: Key Considerations for Follicular Lymphoma Survivors”, June 2018 Newsletter, p. 8-21
  • Avoiding the common error of over supplementation, August 2014 Newsletter, p. 19
  • Study finds excessive use of dietary supplements associated with increased cancer risk, May 2015 Newsletter, p. 20-21
  • Misuse of supplements can be toxic, Article #7, p. 13-17; March 2014 Newsletter, p. 17-18
  • Discussion of wise and unwise use of supplements and pitfalls of promotional diets, Article #7, p. 13-17
  • Dangers of over-using antioxidant supplements, Article #7, p. 13-17

Survival (see Long-Term Survival)

[ return to top ]

________________________________

T

Tart Cherry

  • Anti-inflammatory and sleep benefits , May 2024 Newsletter, p.12-13; March 2024 Newsletter, p. 3-10

T-Cells and Follicular Lymphoma

  • “Breakthrough Research Finds Brief Exercise Activates T Cells in Lymphoma Patients”,  October 2024 Newsletter, p. 3-10
  • “Follicular Lymphoma — Winning the T Cell Game”,  September 2022 Newsletter, p.3-14
  • April 2022 research finds follicular lymphoma survivor’s T cell counts at diagnosis are a significant factor in predicting overall survival (OS),  July 2022 Newsletter, p. 5-8
  • Research links T cell dysfunction to chronic stress and cancer,  May 2022 Newsletter, p. 2-10
  • In depth analysis of the role of T cells in all Four Pillars,  February 2022 Newsletter, p.2-15
  • “The One Factor that Combats both Viruses and Lymphoma”,  September 2021 Mid Month Newsletter, p. 1-13

T-Cell Immunotherapy

  • “CAR-T Casts a Fading Light”,  October 2024 Newsletter, p. 10-14
  • The importance of T cells for natural (spontaneous) regression and the natural strategies associated with healthy T cells, October 2020 Newsletter, p. 4-15
  • Sleep and T cells, Article #3, p. 48-50
  • “Where are we with immunotherapy?”, December 2019 Newsletter, p. 8-11; June 2019 Newsletter, p. 17-22
  • Quality sleep now proven to enhance the effectiveness of CD8+ T cells, a prognostic indicator of longer overall survival with follicular lymphoma, January 2020 Newsletter, p. 10-12
  • Breakthrough natural strategies to enhance T cell effectiveness, June 2017 Newsletter (entire)
  • Lifelong exercisers found to have healthier T cell count and better immune function, April 2018 Newsletter, p. 14-17
  • Sunlight linked to enhanced healthy T cell formation, February 2017 Newsletter, p. 11-13

Targeted Natural Strategies (4PEP) for Long-Term Survival (see also Lifestyle Strategies)

  • “Noteworthy Developments in the Nutrition Pillar”,  May 2024 Newsletter (entire)
  • “Epigenetic Regulators of Follicular Lymphoma: A Reference Guide”, Article #11
  • “Getting Follicular Lymphoma Cells to Die on Their Own”, Article #10
  • “The Four Pillar Epigenetics 4PEP Program”, Article #3
  • Ringleader fNHL genes and enzymes and targeted natural strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-25
  • “Living the Natural Strategies Everyday”, August 2011 Newsletter, p. 3-11
  • Scientific premises for TNS, Article # 10, p. 9-13; Article #3, p. 15-22; Article #11, p. 2-5; 20-24
  • The many advantages of using natural strategies to slow cancer progression, Article #10, p. 1-10
  • Updated dietary and supplementation strategies, Article #3, p. 57-83

Tempo, Discussion of tempo and the “tipping point”, Article #6, p. 5-6

Thrive Zone,  August 2019 Newsletter, p. 15-17

Toxins,  March 2023 Mid Month Newsletter, p. 2-12; March 2022 Newsletter, p. 2-16; Article #11, p. 6-7,  May 2017 Newsletter, p. 4-15; September 2016 Newsletter, p. 4-12October 2013 Newsletter, p. 10-13

TP53 Gene

  • The potency of gene TP53 in influencing follicular lymphoma progression, February 2019 Newsletter, p. 2-4;  November 2015 Newsletter, p. 18-20

Transformation

  • Essential information on follicular lymphoma transformation:  April 2022 Newsletter, p. 9-10; Article #4
  • “A Changing Perspective on Follicular Lymphoma Transformation”, April 2019 Newsletter, p. 16-18
  • “Follicular Lymphoma Transformation — Past, Present and Future (latest research), January 2017 Newsletter, p. 5-9
  • “Latest Genetic Data Predicts Follicular Lymphoma Transformation”,  September 2016 Newsletter, p. 20-22
  • Important updated information on follicular lymphoma transformation, February 2015 Newsletter, p. 11-18
  • SUV uptake values and transformation, February 2015 Newsletter, p. 14-15
  • Interpretation of diffuse pattern results in tissue biopsies as it pertains to diagnosing transformation, Article #5, p. 18-20; Article #7, p. 20-24
  • Genes associated with follicular lymphoma transformation, Article #5, p. 35-36; Article #4, p. 19-20; June 2014 Newsletter, p. 4-8
  • Biopsies and uncertainty re interpretation of pathology results at the time of suspected transformation, Article #4, p. 6-8; Article #5, p. 18-20
  • Have I transformed?, Article #5, 18-20; Article #4, p. 6-8; Article #7, p. 20-24, March 2014 Newsletter, p. 4-7
  • Research identifies specific genes associated with transformation, Article #5, 35-36; Article #4, p. 19-20; March 2014 Newsletter, p. 7-8
  • New chemo treatment R-GCVP developed for patients with heart concerns, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9
  • “Localized” transformation and treatment options, Article #5, p. 17-19; Article #7, p. 22-23
  • Chemotherapy and transformation, Article #4, p. 8-12
  • Understanding transformation, Article #2, p. 33-36; Article #4, p. 1-9; Article #6, p. 5-8; Article #7, p. 20-24
  • Planning for transformation: most important considerations, Article #6, p.13-14
  • Major treatment options for transformation, Article #4, p. 8-12
  • Elevated LDH and transformation, Article #4, p. 5-6
  • Resveratrol and transformation, Article #4, p. 24
  • R-CHOP and transformation, Article #7, p. 19-25; Article #4, p.8-9
  • PET scans and transformation, Article #4, p.6-7
  • B Symptoms and transformation, Article #4, p. 5-6; Article #2, p. 34
  • Treatments for second transformation, Article #4, p. 9-10; Article #6, p.26, Article #7, p.23-24
  • Research study on resveratrol and transformed fNHL cells, June 2009 Newsletter, p. 11-12
  • Prognostic indicators and transformation, Article #4, p. 15-16

Translational Medicine,  May 2020 Newsletter, p. 10-14

Treatment-Wellness Spectrum, August 2012 Newsletter, p. 4-5

Triple Hit Lymphoma,  April 2022 Newsletter, p. 16-17

Tumor Suppressor Genes

  • The importance of tumor suppressor genes in holding fNHL in check, May 2016 Newsletter, p. 15-20; August 2015 Newsletter, p. 9-10; 21-23
  • Description of tumor suppressor genes, December 2016 Newsletter, p. 3-4: August 2015 Newsletter, p. 8-10
  • Managing tumor suppressor gene PTEN with nanotechnology and/or diet, October 2018 Newsletter, p. 7-10
  • Animal research finds reactivation of key tumor suppressor gene can revert cancer cells to normal tissue, July 2015 Newsletter, p. 17-18

Turmeric (see curcumin)

Tyrosine Kinase Inhibitors

  • Natural inhibitors of tyrosine kinases, Article #11, p. 13
  • “Clinical Trial Results with New Kinase Drugs Idelalisib and Imbruvica”, January 2014 Newsletter, p. 12-16
  • Ibrutinib, BTK gene, concerns with immunity, September 2013 Newsletter, p. 3-13

[ return to top ]

__________________________________________________________

U

Urolithin A

  • Breakthrough research — Urolithin A is associated with restoring blood stem cells and lymph nodes, May 2024 Newsletter, p. 14-15; January 2024 Newsletter, p. 3-10; February 2024 Newsletter, p. 2-4

[ return to top ]

_____________________________________________________________

V

Vaccines

  • Flu vaccines, mid-October 2020 Newsletter, p. 1-6
  • Vaccine update re lymphoma,  February 2021 Newsletter, p. 14-15
  • Pneumonia vaccines, August 2019 Newsletter, p. 18-19: October 2017 Newsletter, p. 10
  • Shingles vaccine, August 2019 Newsletter, p. 18-19

Vitamin A,   October 2016 Newsletter, p. 16-20; Article #11, p. 14; December 2015 Newsletter, p. 14-18; April 2015 Newsletter, p. 14-16, February 2016 Newsletter, p. 14-22.

Vitamin B Complex

  • Vitamin B complex, ATP and energy,  June 2024 Newsletter, p. 7-13
  • Update on vitamin B complex supplements,  June 2022 Newsletter, p. 17-18
  • “Vitamin B — Now More than Ever”,  April 2022 Mid Month Newsletter, p. 2-18
  • “Vitamin B: Vital to Optimize — Challenging but Doable”, November 2019 Newsletter, p. 15-20
  • Folate (B9), May 2019 Newsletter, p. 3
  • Vitamin B — Overlooked for Far Too Long, June 2016 Newsletter, p. 7-12
  • Vitamin B6 — anti-anxiety strategy when coupled with magnesium, June 2020 Newsletter, p. 11
  • Riboflavin (B2) essential for healthy gut bacteria, October 2018 Newsletter, p. 3-7
  • Updated information on B complex, including folate, MTHFR gene, and homocysteine, mid-June 2020 Newsletter, p. 1-10; March 2018 Newsletter, p. 4-16
  • Updated information on supplementing with B complex, April 2018 Newsletter, p. 18-21

Vitamin C, November 2017 Newsletter, p. 9-12

Vitamin D

  • Importance of vitamin D testing for lymphoma survivors,  August 2024 Newsletter, p. 5-8
  • Vitamin D update for 2024, June 2024 Newsletter, p. 13-19
  • Vitamin D, diet and the gut microbiome, May 2024 Newsletter, p. 8-10
  • Vitamin D and T Cells,  September 2022 Newsletter, p. 5-6
  • “Understanding How Vitamin D Extends Overall Survival”, January 2022 Newsletter, p. 5-12
  • “COVID-19? Prominent New Research Supports Vitamin D”, mid-September 2020 Newsletter, p. 1-9
  • “Important New Insights re Vitamin D”,  December 2020 Newsletter, p. 1-7
  • “Effects of Vitamin D on Follicular Lymphoma Survival: Reinforcing the Latest Data”, October 2019 Newsletter, p. 9-12
  • The importance of making sure your vitamin D level is optimized before taking treatment, January 2020 Newsletter, p. 17-19
  • Epigenetic anticancer effects of vitamin D, Article #10, p.13-16; Article #11, p. 18
  • Vitamin D levels linked to changes in gut microbiome after UVB (light) exposure, December 2019 Newsletter, p. 16-19
  • The vital necessity of vitamin D for follicular lymphoma survivors, May 2016 Newsletter, p. 20-24, Article #3, p.22-24
  • 2017 research links clinical failure with low vitamin D levels in fNHL survivors, October 2017 Newsletter, p. 11-13; Article #3, p. 27-31
  • 2016 research finds insufficient vitamin D levels are directly linked to higher relapse rates and inferior overall survival in follicular lymphoma survivors, July 2016 Newsletter, p. 10-15
  • Not optimizing vitamin D is a strategic error for fNHL patients, April 2015 Newsletter, p. 18-20
  • Low vitamin D levels in fNHL patients found to be “surprisingly strong” prognostic indicators for overall survival (OS) outcomes, May 2015 Newsletter, p. 4-6; Article #10, p. 14; December 2012 Newsletter, p. 6-8
  • Vitamin D and intestinal health, October 2016 Newsletter, p. 9-10
  • Vitamin D and the flu, March 2018 Newsletter, p. 18-19
  • Epigenetics, vitamin D, follicular lymphoma, natural regression, and the Myc gene, Article #11, p. 18-19
  • Ensuring a year-round optimum level of Vitamin D, Article #7, p. 11-13; Article #3, p. 24-34
  • Using vitamin D as a prognostic indicator of survival, Article #2, p. 29-31
  • Vitamin D testing information, Article #5, p. 25-26; July 2016 Newsletter, p. 15; April 2011 Newsletter, p. 21, Article #3, p.28
  • Clinical research studies on cancer and Vitamin D levels
    • Vitamin D follicular lymphoma study reports low serum vitamin D levels associated with inferior overall survival, July 2016 Newsletter, p. 10-15; May 2015 Newsletter, p. 4-6
    • Summary of 2012 vitamin D research study from Norway association with overall survival in lymphoma patients, April 2013, p. 10-12
    • Vitamin D found to inhibit the production and function of protein cMyc, which helps to drive cancer cell division, February 2013 Newsletter, p. 6-8
    • Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, March 2013 Newsletter, p.17-18
  • Vitamin D supplements and dosage considerations; Article #3, p. 25-26
  • Barriers in achieving optimal Vitamin D levels, June 2009 Newsletter, p. 4-9
  • Fat solubility and supplementation, Article #3, p. 25-26

Vitamin E

  • Epigenetic anti-cancer effects of tocotrienols in vitamin E,  February 2019 Newsletter, p. 5; Article #11, p.17
  • Vitamin E tocotrienols found to reduce damage from radiation scanning, July 2013 Newsletter, p. 19-22
  • Red palm oil as a full-spectrum source of Vitamin E, Article #7, p. 47

Vitamin K

  • Vitamin K2 and osteoporosis, August 2024 Newsletter, p. 8-13
  • Update on vitamin K2 supplements,  June 2022 Newsletter, p.13-15
  • “Vitamin K — Platelets, Osteoporosis, and MK-7”, August 2020 Newsletter, p. 12-16
  • “Vitamin K2 Must Accompany Vitamin D: Here’s Why”, June  2020 Newsletter, p. 5-6; January 2014 Newsletter, p. 18-21
  • Epigenetic anti-cancer effects of vitamin K-2, December 2019 Newsletter, p. 4; Article #11, p.19

Vorinostat, Article #6, p. 31-32

[ return to top ]

________________________________________________________

W

Walnuts, March 2020 Newsletter, p. 5-6; May 2019 Newsletter, p. 17-21; September 2017 Newsletter, p.19-21

Water

  • Tap water safety and lymphoma,  April 2023 Newsletter, p. 3-8

Warburg, Dr. Otto

  • Summary description of the “Warburg Effect” and its importance in getting follicular lymphoma cells to die on their own, Article #10, p. 6-7
  • Dr. Warburg’s contributions to understanding cancer causation, June 2010 Newsletter, p. 3-6
  • Dr. Warburg’s theory about cancer and lack of effective mitochondrial function in cancer cells, Article #10, p. 12-14; November 2010 Newsletter, p.10

Watch and wait (see Dynamic Observation)

Wheatgrass, February 2013 Newsletter, p. 16-17

Whey Protein

  • Whey protein powders should be avoided by fNHL patients, Article #10, p. 26-27; June 2013 Newsletter, p. 13-14: Article #7, p. 43-44; Article #3, p. 14 and 67-6

Will to Live, Article #3, p. 76

Working Cure for Follicular Lymphoma

  • Detailed examination of items of significance in the Follicular Lymphoma Working Cure Plan, February 2024 Newsletter, p. 5-17
  • “Moving Ahead with New Knowledge Toward a Working Cure for Follicular Lymphoma”, December 2023 Newsletter, p. 3-14
  • “Ten Essential Strategies to Achieve a Follicular Lymphoma Working Cure”, November 2022 Newsletter,  p. 5-19

[ return to top ]

________________________________________________________

X

[ return to top ]

________________________________________________________

Y

Yogurt

  • “Eight Reasons to Choose Yogurt over Milk”, September 2018 Newsletter, p. 19-10
  • Article #3, p. 70; April 2015 Newsletter, p. 21-23
  • Fermented milk products a healthier choice than milk, June 2016 Newsletter, p. 13-15;  May 2015 Newsletter, p. 22-23
  • “Six Reasons Why Yogurt is Essential”, March 2015 Newsletter, p. 17-19
  • Yogurt as source for probiotics and calcium, October 2016 Newsletter, p. 9; Article #11, p.12
  • Yogurt boosts the brain, December 2016 Newsletter, p. 8-11
  • Information on making homemade yogurt, October 2013 Newsletter, p. 16-18

[ return to top ]

________________________________________________________

Z

Zevalin

  • General information, Article #6, p.25

Zinc, mid-August 2020 Newsletter, p. 1-7

[ return to top ]

*******

Providing survivors with new knowledge needed to overcome follicular lymphoma.